

## (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)


(19) World Intellectual Property Organization  
International Bureau(43) International Publication Date  
18 December 2003 (18.12.2003)

PCT

(10) International Publication Number  
WO 03/103577 A2

- (51) International Patent Classification: A61K (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (21) International Application Number: PCT/US03/17442
- (22) International Filing Date: 4 June 2003 (04.06.2003)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 60/386,932 6 June 2002 (06.06.2002) US
- (71) Applicant and (72) Inventor: WUN, Tze, Chein [US/US]; 613 Hantley Heights Drive, Ballwin, MO 63021-3020 (US).
- (74) Agent: NEALEY, Tura, A.; Sonnenschein Nath & Rosenthal, Attention: IP Department - St. Louis Office, P.O. Box 601080, Wacker Drive Station - Sears Tower, Chicago, IL 60606-1080 (US).
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SI, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
- Published: — without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: NOVEL RECOMBINANT ANTICOAGULANT PROTEINS



(57) Abstract: Novel recombinant anticoagulation proteins, methods of their use and methods of their production are described. In particular, recombinant fusions of annexin V (ANV) and Kunitz protease inhibitors (KPI) that possess potent anticoagulant activity are provided. The fusions, abbreviated ANV:KPI, utilize ANV having high affinity for phosphatidyl-L-serine with various KPI's to target serine proteases in membrane-associated coagulation complexes in the blood coagulation cascade. ANV:KPIs are potentially useful antithrombotic drugs permitting localized passivation of thrombogenic vessel walls and associated thrombi.

WO 03/103577 A2

### Novel Recombinant Anticoagulant Proteins

This application claims priority from provisional U.S. Application No. 60/386932, filed June 6, 2002, the disclosure of which is herein incorporated by reference in its entirety.

5

### Background of the Invention

The present invention relates in general to anticoagulant proteins, and in particular to novel recombinant blood coagulation inhibitors.

Tissue factor (TF) is generally considered to be the physiological trigger of the blood coagulation in normal hemostasis and in a variety of coagulopathic and thrombotic diseases. TF is an integral membrane protein that is normally present on the surface of certain extra-vascular cell types, but can also be induced to express on endothelium and monocytes upon stimulation [reviewed in (1)]. Based on studies in whole blood and re-constituted plasma systems (2-5), the key events of TF-initiated blood clotting can be schematically illustrated as in Fig. 1. Upon exposure, TF forms a complex with factor VII/VIIa present in the circulating blood. The resulting extrinsic tenase complex (TF/VIIa) initiates the clotting cascade by activating small amounts of factors IX and X on the TF-bearing cells/microparticles. The TF/VIIa-activated factors IXa and Xa play distinct roles in the subsequent coagulation reactions. In a complex with factor Va/V on TF-bearing membrane surface, factor Xa generates a small amount of thrombin that partially activates platelets, cleaves fibrinogen to form an initial clot, and converts factors V, VIII, and XI to their active forms. Subsequent to this initiation phase, propagation of thrombin generation begins. During the propagation phase, activated platelets provide an anionic membrane surface for the assembly of intrinsic tenase (VIIIa/IXa) and prothrombinase (Va/Xa) complexes, which very efficiently activate factor X and prothrombin, respectively, leading to explosive thrombin generation and consolidation of the fibrin-platelet plug. Three plasma anticoagulant systems regulate the clotting cascade, each acting at a different point in the cascade. Tissue factor pathway inhibitor (TFPI) influences the initiation phase by forming a TFPI-Xa inhibitory complex that inhibits TF/VIIa through feedback inhibition; antithrombin III (AT III) primarily exerts its effect by inhibiting free thrombin and Xa in the propagation phase; and activated protein C (APC) affects the duration of the propagation by proteolytically inactivating Va and VIIIa.

30

The availability of anionic phospholipid, chiefly phosphatidyl-L-serine (PS), is important for the assembly and expression of catalytic activities of the membrane-associated coagulation enzyme complexes (extrinsic tenase, intrinsic tenase, prothrombinase and XIa) that drive the initiation and propagation of the coagulation cascade. Plasma membrane phospholipids of mammalian cells are normally asymmetrically distributed, with PS being exclusively sequestered in the inner membrane leaflet (6). Because of PS sequestration, intact quiescent cells are normally not procoagulant. In circumstances of cell activation, cell injury, or in response to apoptotic stimuli, phospholipid asymmetry across the plasma membrane collapses, resulting in exposure of PS on the membrane surface and shedding of membrane "microparticles". The exposure of PS allows assembly of enzyme/cofactor complexes and interaction with their substrates on the membrane surface, thereby enhancing the efficiency of the coagulation reactions (7-9). TF/VII(a) complex formed on intact cells is often cryptic in enzymatic activity towards its substrates. A many fold increase in TF/VIIa activity (de-encryption) is observed when PS becomes available on the membrane surface after cell disruption, treatments with various agents, or induction of apoptosis (10-14). The rate of factor X activation by TF reconstituted with vesicles composed of phosphatidylcholine (PC) alone is less than 5 % of that observed with PS-PC vesicles (15). These observations suggest that concomitant expression of TF and exposure of PS on the membrane surface are important in the initiation of coagulation. In the processes of hemostasis/thrombosis, platelets are known to provide an anionic membrane surface for the assembly of intrinsic tenase (VIIIa/IXa) and prothrombinase (Va/Xa) (7,16). Upon platelet activation, PS rapidly appears on the platelet membrane surface. Interaction of factor VIIIa with the anionic lipid creates a  $\text{Ca}^{++}$ -dependent high-affinity binding site for factor IXa, leading to the formation of the intrinsic tenase complex. Likewise, binding of factor Va to anionic lipid promotes  $\text{Ca}^{++}$ -dependent binding of factor Xa, forming the prothrombinase complex. Factor XIa also depends on the PS-exposed membrane for efficient catalysis of the conversion of factor IX into factor IXa.

TFPI is a multivalent Kunitz-type inhibitor that regulates the initiation of the tissue factor pathway of coagulation in the human vascular system (17). TFPI inhibits factor Xa directly, and in a factor Xa-dependent manner, produces a feedback inhibition of TF/VIIa complex and thus dampens the protease cascade of the tissue factor pathway. Although TFPI is physiologically very important in the regulation of tissue factor pathway, its

development for clinical antithrombotic therapy is currently limited by the large doses required for it to effectively interrupt vascular thrombosis (18-20).

Several other, naturally occurring Kunitz-type inhibitors that bind factors VIIa, IXa, Xa, and XIa of the tissue factor pathway have also been described. These include leech-derived Antistasin (ATS) (21), Tick Anticoagulant Peptide (TAP) (22), and two *Ancylostoma caninum* Anticoagulant Peptides (AcAP5 and AcAP6) (23) that inhibit factor Xa specifically; another *Ancylostoma caninum* Anticoagulant Peptide (AcAPc2) that inhibits VIIa (23); and a Kunitz-inhibitory domain of amyloid  $\beta$ -protein precursor ( $K_{APP}$ ) that inhibits factors VIIa, IXa, Xa, and XIa (24-27). Using site-specific mutagenesis and phage display technology, two series of  $K_{APP}$  and aprotinin (bovine pancreatic trypsin inhibitor) homologs with very high affinity (sub-nanomolar  $K_i$ ) toward different coagulation proteases (TF/VIIa, Xa, XIa, and Kallikrein etc.) have been created (28-31). However, the anticoagulant potencies of these mutants are quite low in *in vitro* coagulation assays (tissue factor-initiated clotting and activated partial thromboplastin time). The aprotinin homologs also require very high doses to achieve antithrombotic effect in an *in vivo* vascular trauma model (31).

### Brief Summary of the Invention

In accordance with the present invention, novel recombinant anticoagulant proteins, methods and materials relating to their production, and methods of their use in treatment are provided.

A novel series of recombinant anticoagulant fusion proteins are preferably created by linking annexin V (ANV) (SEQ ID NO: 10), a phosphatidylserine (PS) binding protein, to Kunitz-type protease inhibitors (KPI) targeting the serine proteases in the enzymatic complexes. The resulting fusion proteins exhibit much stronger anticoagulant activities than their component proteins. Several of these constructs possess far greater potencies than TFPI, the natural inhibitor of TF-initiated coagulation in blood. The annexinV:Kunitz-type inhibitor (ANV:KPI) fusions represent a new class of anticoagulants that specifically target the coagulation enzyme complexes on the procoagulant PS-exposed membrane surface, and are useful as anti-thrombotic therapeutic agents with an ability to passivate thrombogenic vessel wall and associated thrombi.

Therefore, in one embodiment there are provided recombinant anticoagulant proteins, each comprising a fusion of annexin V (ANV) (SEQ ID NO: 10) and a Kunitz protease inhibitor (KPI). Alternative embodiments of the recombinant anticoagulant protein include, for example, fusion of ANV with Tick Anticoagulant Peptide (TAP) (SEQ ID NO: 1), with a variant of aprotinin (6L15) (SEQ ID NO: 2), with the Kunitz-inhibitory domain of amyloid  $\beta$ -protein precursor ( $K_{APP}$ ) (SEQ ID NO: 3), and with  $KK_{TFPI\ 22-160}$  (SEQ ID NO: 4).

In another embodiment there is provided an antithrombotic composition comprising a recombinant anticoagulant protein comprising a fusion of annexin V (ANV) (SEQ ID NO: 10) and a Kunitz protease inhibitor (KPI). Alternative embodiments of the antithrombotic composition include, for example, TAP-ANV (SEQ ID NO: 1), ANV-6L15 (SEQ ID NO: 2), ANV- $K_{APP}$  (SEQ ID NO: 3), and ANV- $KK_{TFPI\ 22-160}$  (SEQ ID NO: 4).

In another embodiment there is provided a method of inhibiting blood coagulation in a mammalian subject comprising administering to the subject an effective amount of a recombinant anticoagulant protein comprising a fusion of annexin V (ANV) (SEQ ID NO: 10) and a Kunitz protease inhibitor (KPI).

In another embodiment there is provided a method of producing a recombinant anticoagulant protein comprising linking annexin V (ANV) (SEQ ID NO: 10) and a Kunitz protease inhibitor (KPI).

In another embodiment there is provided a method of treating or preventing an excess of thrombotic activity in a subject in need of such treatment or prevention, said method comprising administering to the subject an effective amount of an antithrombotic composition comprising a fusion of annexin V (ANV) (SEQ ID NO: 10) and a Kunitz protease inhibitor (KPI).

In another embodiment there is provided a recombinant DNA molecule comprising a first DNA sequence encoding annexin V (ANV) (SEQ ID NO: 9) and second DNA sequence encoding a Kunitz protease inhibitor (KPI). Alternative embodiments of the recombinant DNA molecule include, for example, DNA sequences selected from the group consisting of TAP-ANV (SEQ ID NO: 5), ANV-6L15 (SEQ ID NO: 6), ANV- $K_{APP}$  (SEQ ID NO: 7), and ANV- $KK_{TFPI}$  (SEQ ID NO: 8), or conservatively substituted variants thereof.

In another embodiment there is provided a process for the preparation of a cell line expressing a recombinant anticoagulant protein comprising a fusion of annexin V (ANV) (SEQ ID NO: 10) and a Kunitz protease inhibitor (KPI), the process comprising stably transfecting a host cell with a recombinant expression vector comprising a cDNA sequence encoding ANV or conservatively substituted variants thereof, and a cDNA sequence encoding a KPI.

In another embodiment there is provided a recombinant expression vector comprising a first nucleotide sequence encoding annexin V (ANV) (SEQ ID NO: 9), Cys<sup>315</sup>-to-Ala mutation of ANV (SEQ ID NO: 14), or conservatively substituted variants thereof, and a second nucleotide sequence of a Kunitz protease inhibitor (KPI) together with additional sequences capable of directing the synthesis of a recombinant anticoagulant protein comprising a fusion of ANV and a KPI, in a culture of stably transfected cells. Alternative embodiments of the recombinant expression vector include, for example, a nucleotide sequence selected from the group of TAP-ANV (SEQ ID NO: 5), ANV-6L15 (SEQ ID NO: 6), ANV-K<sub>APP</sub> (SEQ ID NO: 7), and ANV-KK<sub>TFPI</sub> (SEQ ID NO: 8), or conservatively substituted variants thereof.

### Brief Description of the Drawings

**Fig. 1. Schematic of TF-initiated clotting.**

Factor VII binds to TF and is activated to VIIa on the TF-bearing cells/microparticles. The TF/VIIa complex activates both factor IX and factor X. The factor Xa generates a small amount of thrombin (IIa) locally. This small amount of thrombin activates platelets, activates factor V, releases factor VIII from von Willebrand factor and activates it, and activates factor XI. TF/VIIa-activated IXa can then bind to the VIIIa on the activated platelet to form an intrinsic tenase (VIIIa/IXa) that activates factor X efficiently. The platelet-generated Xa binds Va to form a prothrombinase (Va/Xa) that promotes large-scale conversion of prothrombin (II) to thrombin. Three plasma anticoagulant systems regulate the coagulation cascade: TFPI directly inhibits Xa, and in a Xa-dependent manner produces a feedback inhibition of TF/VIIa; AT III mainly inhibits Xa and thrombin; and APC proteolytically inactivates Va and VIIIa. Adapted from Roberts et al. (5) and Mann K et al. (3).

**Fig. 2. Schematic of annexin V and its fusion products with various Kunitz-type inhibitors.**

ANV, annexin V (SEQ ID NO: 10); TAP-ANV (SEQ ID NO: 1), ala-tick anticoagulant peptide linked to annexin V by Gly-Ser dipeptide; ANV-6L15 (SEQ ID NO: 2), annexin V  
 5 linked to 6L15 (a Kunitz inhibitor with high affinity for TF/VIIa); ANV-K<sub>APP</sub> (SEQ ID NO: 3), annexin V linked to K<sub>APP</sub> (Kunitz inhibitory domain of amyloid  $\beta$ -protein precursor); ANV-KK<sub>TFPI</sub> (SEQ ID NO: 4), annexin V linked to KK<sub>TFPI</sub> (TFPI<sub>122-161</sub> containing Kunitz-1 and Kunitz-2 domains).

**Fig. 3. SDS-PAGE analysis of purified ANV and its fusion products with various Kunitz-type protease inhibitors.**

Samples were analyzed by 12% SDS-PAGE under non-reducing (A) or reducing (B) conditions followed by Coomassie blue staining. All samples were boiled for 3min without (A), or with (B) 50 mM dithiothreitol. Approximately 5  $\mu$ g proteins were loaded on each  
 15 lane. Lane 1, molecular weight marker; lane 2, ANV-KK<sub>TFPI</sub> (SEQ ID NO: 4); lane 3, ANV-6L15 (SEQ ID NO: 2); lane 4, TAP-ANV (SEQ ID NO: 1); lane 5 ANV-K<sub>APP</sub> (SEQ ID NO: 3); lane 6, ANV (SEQ ID NO: 10).

**Fig. 4. Inhibition of porcine trypsin and bovine factor Xa by various purified inhibitors.**

Inhibitions of trypsin and bovine factor X were measured by amidolytic assays as described in Methods herein below. The concentrations of active trypsin and bovine factor Xa were determined by active site titration with 4-nitrophenyl *p*'-guanidinobenzoate (41,42). The concentrations of purified inhibitors were determined by absorbance measurement at  
 25 280nm using molar extinction coefficients of 28170, 7120, 39550, 18500, 31300, and 30170 for ANV-6L15, 6L15, TAP-ANV, TAP, ANV-K<sub>APP</sub>, and ANV-KK<sub>TFPI</sub>, respectively. (A) Inhibition of trypsin by ANV-6L15; (B) Inhibition of trypsin by 6L15; (C) Inhibition of factor Xa by TAP-ANV; (D) Inhibition of factor Xa by TAP; (E) Inhibition of trypsin by ANV-K<sub>APP</sub>; (F) Inhibition of factor Xa by ANV-KK<sub>TFPI</sub>.

**Fig. 5. Effects of various inhibitors in activated partial thromboplastin time (APTT) assay.**

APTT assay was carried out using an ACL 200 Coagulometer and APTT-SP reagent (Instrument Laboratories). Pooled human plasma (180  $\mu$ l) was mixed with 20  $\mu$ l of various  
5 inhibitors to attain the indicated final concentrations for the assay. The plasma with control buffer had a clotting time of 40.7 sec. TFPI (m) refers to mammalian C127 cell-derived FL-TFPI.

### Detailed Description of the Invention

10 The following detailed description of the invention taken in conjunction with the accompanying drawings is provided to further illustrate the invention and preferred embodiments in greater detail.

The blood coagulation cascade proceeds primarily via the formation of coagulation enzyme complexes, each consisting of a serine protease associated with a membrane-bound  
15 cofactor/receptor on an anionic membrane surface. These complexes are conventionally named extrinsic tenase (factor VIIa-tissue factor), intrinsic tenase (factor IXa-factor VIIIa), prothrombinase (factor Xa-factor Va) and XIa complex.

As described herein, a novel series of recombinant anticoagulant fusion proteins are created, for example, by linking annexin V (ANV) (SEQ ID NO: 10), a phosphatidylserine  
20 (PS) binding protein, to a Kunitz-type protease inhibitor (KPI) targeting the serine proteases in the enzymatic complexes. The resulting fusion proteins exhibit much stronger anticoagulant activities than their component proteins alone or even additively. For convenience, these recombinant anticoagulant fusion proteins are abbreviated ANV:KPI. These fusion proteins utilize the high affinity of ANV for phosphatidyl-L-serine (PS) (32)  
25 and various KPI's for inhibition of the serine proteases in membrane-associated coagulation complexes in the blood coagulation cascade. Several of these novel constructs possess far greater potencies than TFPI, the natural inhibitor of TF-initiated coagulation in blood. The annexinV:Kunitz-type protease inhibitor (ANV:KPI) fusion proteins represent a new class of anticoagulants that specifically target the coagulation enzyme complexes on  
30 the procoagulant PS-exposed membrane surface, and are useful as anti-thrombotic therapeutic agents with an ability to passivate thrombogenic vessel wall and associated thrombi. The novel fusion proteins will be useful in the treatment of diseases and



conditions involving an excess of thrombogenesis, including arterial thrombotic events such as unstable angina, myocardial infarction, sudden cardiac death, ischemic stroke, ruptured aneurisms, intermittent claudication, and critical limb ischemia; venous thrombosis such as deep venous thrombosis, pulmonary embolism, thrombophlebitis, and chronic venous insufficiency; and other clinical conditions such as surgical thrombosis, prosthetic heart valve, atherosclerosis, restenosis, ischemia reperfusion injury, sepsis, disseminated intravascular coagulation, acute lung injury, malignancy, chronic renal failure, nephrotic syndrome, crescentic glomerulonephritis, diabetes, sickle cell anemia, thalassemia, antiphospholipid syndrome, extra-corporeal circulation, hemodialysis, peritoneal dialysis and annexinopathies.

In order to further illustrate the invention, the following specific laboratory examples were carried out although it will be understood that the invention is not limited to these specific examples or the details described therein.

## EXAMPLES

### Materials and Methods

#### Reagents

Urea (sequenal grade) and Brij 35 were obtained from Pierce. Mixed bed resin AG501-X8, SDS-PAGE reagents, and molecular weight markers were purchased from BioRad. Dade Innovin<sup>®</sup> was from Baxter Diagnostics Inc. (Deerfield, IL). APTT-SP was from Instrumentation Laboratory (Lexington, MA). Bovine factor Xa was supplied by American Diagnostica, Inc. (Greenwich, CT). Trypsin, *p*-nitrophenyl *p*'-guanidinobenzoate HCl, bovine brain extract, cholesterol, and diacetylphosphate were from Sigma (St. Louis, MO). The synthetic substrates, S2444 and S2765 were obtained from diaPharma (West Chester, OH). Freshly frozen human plasma was purchased from Taipei Blood Center. Mammalian C127 cell- and *E. coli*- derived recombinant TFPIs were prepared as described before (33,34). Recombinant X-K1 (C-terminal peptide of human factor X fused with the first Kunitz domain of TFPI) (35), and TFPI1-160 were gifts of Dr. George Broze, Jr., (Washington University). Yeast-derived recombinant TAP was a gift from Dr. Dana Abendschein (Washington University).

### Cloning of cDNA for annexin V

ANV cDNA, lacking an initiation Met codon and a stop codon, was generated from human placental mRNA by PCR using ANV reverse primer 1 (5'-ATCAAGCTTATGCAT GTCATCTTCTCCACAGAG-3') (SEQ ID NO: 11) and forward primer 2 (5'-  
 5 GATCGGAT CCACTCTGGTCTGCTTCACCTT -3') (SEQ ID NO: 12). ATGCAT is the site of restriction enzyme *Nsi* I used for ligating the 6L15,  $K_{APF}$ , or  $KK_{TFP122-161}$  gene fragment. ANV cDNA mutation of Cys<sup>315</sup>-to-Ala was created by PCR using oligonucleotide X (5'-CG TGACATGCATGTCATCTTCTCCAGCGGAGCA-3') (SEQ ID NO: 13), in which the bolded GC was changed from CA in order to replace the original  
 10 codon of Cys into Ala. Recombinant ANV was expressed without mutation of Cys<sup>315</sup>. For all other ANV: KPI fusions, ANV cDNA with Cys<sup>315</sup>-to-Ala mutation (SEQ ID NO: 14) was used. The position of Cys/Ala was numbered as 315 in the PCR-amplified ANV cDNA lacking an initiation Met codon.

### 15 Construction of 6L15, TAP, and $K_{APF}$ genes

The synthetic gene encoding 6L15 was constructed from 3 pairs of overlapping oligonucleotides. The three forward oligomers are: BP-1 (5'-TCCGGACTTCTGCCT GGAACCGCCGTACGACGGTCCGTGCGTCTCTGCACCTGCGTTACTTCTC-3') (SEQ ID NO: 15); BP-2 (5'-TACAATGCAAAGGCAGGCCTGTGTCTCAGACCTTCTA  
 20 CTACGGCGGTTG CCTGGCTAAGCGT-3') (SEQ ID NO: 16); and BP-3 (5'-AACAA CTTCGAATCCGCGGAACACTGCATGCGTACTTGCAGTGGTGCTTA-3') (SEQ ID NO: 17). The three reverse oligomers are: BP-1-3' (5'-ACGCAGGTGCAGACGACGGCA CGGACCGTCGTACGGCGGTTCCAGGCAGAAAGTCCGGATATGCAT-3') (SEQ ID NO: 18); BP-2-3' (5'-AGCCAGGCAACCGCCGTAGTAGAA  
 25 GGTCTGACACAGGCCTGCC TTTGCATTGTAGAAGTA-3') (SEQ ID NO: 19); and BP-3-3' (5'-AGCTTAAGCAC CACCGCAAGTACGCATGCAGTCTTCCGCGGATTCGAAGTTGTTACGCCTT-3') (SEQ ID NO: 20); . The internal oligomers were phosphorylated with  $T_4$ -polynucleotide kinase. The three complementary oligonucleotide pairs were annealed separately by  
 30 heating to 95° and slow cooling to room temperature. The annealed oligonucleotide pairs were then ligated with  $T_4$ -DNA ligase to form 6L15 gene. The *Nsi*I restriction enzyme site ATGCAT was designed in the oligomer sequence of BP-1-3' by changing original codon of Arg<sup>1</sup> into His for the ligating to the ANV gene fragment. For expression of 6L15, the

original codon of Arg<sup>1</sup> was replaced by Ala. The synthetic 6L15 gene consists of the following sequence:

GCT CCG GAC TTC TGC CTG GAA CCG CCG TAC GAC GGT CCG TGC CGT GCT  
CTG CAC CTG CGT TAC TTC TAC AAT GCA AAG GCA GGC CTG TGT CAG ACC  
5 TTC TAC TAC GGC GGT TGC CTG GCT AAG CGT AAC AAC TTC GAA TCC GCG  
GAA GAC TGC ATG CGT ACT TGC GGT GGT GCT TAA (SEQ ID NO: 21).

The synthetic ala-TAP gene was synthesized from synthetic oligonucleotides according to Neept et al. (36). The synthetic ala-TAP gene consists of the following sequence:

10 GCT TAC AAC CGT CTG TGC ATC AAA CCG CGT GAC TGG ATC GAC GAA TGC  
GAC TCC AAC GAA GGT GGT GAA CGT GCT TAC TTC CGT AAC GGT AAA GGT  
GGT TGC GAC TCC TTC TGG ATC TGC CCG GAA GAC CAC ACC GGT GCT GAC  
TAC TAC TCC TCC TAC CGT GAC TGC TTC AAC GCT TGC ATC TAA (SEQ ID  
NO: 22);

15 The synthetic K<sub>APP</sub> gene with flanking sequences was constructed from two pairs of overlapping synthetic oligonucleotides. The two forward oligomers are: K<sub>APP</sub>-1 (5'-GGCC CTACCCACAGATACGGAGTTGCCACCACTGAACTTGAGGTTGTTAGAGAGG TTTGTCTGAGCAAGCTGAGACTGGTCCATGTAGAGCTATGATTTCTAGATGGT ACTTCGACGTT-3') (SEQ ID NO: 23); , and K<sub>APP</sub>-2 (5'-ACTGAGGGTAAGTGTGCT CCATCTCTCTACGGTGGTTGTGGTGGTAACAGAAACAACCTTCGACACTGAGGA GTACTGTATGGCTGTGTTGTGGTCTGCTATTTAAATGCATTGATGA-3') (SEQ ID NO: 24). The two reverse oligomers are: K<sub>APP</sub>-1-3'(5'-CTCAGTAACGTCGAAGTACCA TCTAGAAATCATAGCTCTACATGGACCAGTCTCAGCTTGCTCAGAACAAACCTC TCTAACAACTCAAGTTTCAGTGGTGGCAACTCCGTATCTGTGGGTAG-3')  
20 (SEQ ID NO: 25); and K<sub>APP</sub>-2-3'(5'-AGCTTCATCAATGCATTTAAATAGCAGAACC ACAAACAGCCATACAGTACTCTCAGTGTGCAAGTTGTTCTGTTACCACCACA ACCACCGTAGAAGAATGGAGCACACTTACC-3') (SEQ ID NO: 26). The underlined are complementary sequences coding for the K<sub>APP</sub> domain. The oligomers were phosphorylated with T<sub>4</sub>-polynucleotide kinase and annealed by heating to 95° and slow  
25 cooling to room temperature. The annealed oligonucleotide pairs were then ligated with T<sub>4</sub>-DNA ligase. The K<sub>APP</sub> domain of the synthetic gene consists of the following sequence:  
30 GAG GTT TGT TCT GAG CAA GCT GAG ACT GGT CCA TGT AGA GCT ATG AIT

TCT AGA TGG TAC TTC GAC GTT ACT GAG GGT AAG TGT GCT CCA TTC TTC  
 TAC GGT GGT TGT GGT GGT AAC AGA AAC AAC TTC GAC ACT GAG GAG  
 TAC TGT ATG GCT GTT TGT GGT TCT GCT ATT TAA (SEQ ID NO: 27)

## 5 Construction of *E. coli* expression plasmids

- To construct the plasmids for expression of ANV-6L15 and ANV-KK<sub>TFPI</sub>, the following primers were used for PCR amplification and subcloning into pET20b expression vector: ANV-nde (5'- G GAATTCCATATGGCACAGGTTCTCAGAGG-3') (SEQ ID NO: 28), ANV-nsi (5'-CCAATGCATGTCATCTTCTCCAGC-3') (SEQ ID NO: 29),
- 6L15-nsi (5'-CCAATGCATCCGGACTTCTGCCTG-3') (SEQ ID NO: 30),  
 KK<sub>TFPI</sub>-nsi (5'-CCAATGCATTCATTTGTGCATTC-3') (SEQ ID NO: 31),  
 6L15-sal (5'-ACGCGTCGACTTTA AGCACCACCGCAAG-3') (SEQ ID NO: 32), and  
 KK<sub>TFPI</sub>-sal (5'- ACGCGTCGACTTTAGGTTCCATA ATTATCC-3') (SEQ ID NO: 33).
- The sequence underlined is a *Nde* I restriction enzyme site and boxed is the cutting site for *Sal* I. The underlined ATGCAT is *Nsi* I restriction enzyme site used for gene fusion. The enlarged ATG is the initiation codon of Met and the TTA is a complimentary sequence to the stop codon of TAA. The KK<sub>TFPI2-161</sub> gene fragment was obtained by PCR amplification from a full-length TFPI cDNA clone (34) using primers KK<sub>TFPI</sub>-nsi (SEQ ID NO: 31) and KK<sub>TFPI</sub>-sal (SEQ ID NO: 33). The PCR amplified gene fragment of ANV was digested with *Nde*I and *Nsi*I restriction enzymes and linked to *Nsi*I and *Sal*I digested 6L15 (or KK<sub>TFPI</sub>) PCR fragment. The fusion gene was ligated into the expression vector of pET20b(+) which was linearized with *Nde*I and *Sal* I restriction enzymes.

- To construct the plasmid for expression of TAP-ANV, the following primers were used for gene fusion and subcloning into pET20b:

TAP-nde (5'- GGAATTCATATGGCITACAACCGTCTGTG-3') (SEQ ID NO: 34);  
 TAP-bam (5'- CGGGATCCGATGCAAGCGTTGAAGCAG-3') (SEQ ID NO: 35);  
 ANV-bam (5'- CGGGATCCGCACAGGTTCTCAGAGGC-3') (SEQ ID NO: 36);  
 ANV-sal (5'- ACGCGTCGACTTTAGTCATCTTCTCCAGCG-3') (SEQ ID NO: 37).

The PCR amplified gene fragment of TAP was digested with *Nde*I and *Bam*HI restriction enzymes and linked to *Bam*HI and *Sal*I digested ANV gene fragment. The fusion gene was inserted into the expression vector of pET20b(+) which was also linearized with *Nde*I and *Sal*I restriction enzymes.

- 5        The desired recombinant plasmids were screened by PCR and DNA sequence determination. The expression plasmids are designated pET20b-AB8, pET20b-AKK11, and pET20b-TAP-A, which expressed intracellularly the recombinant proteins of ANV-6L15 and ANV-KK<sub>TFF</sub>, and TAP-ANV, respectively, in *E. coli* under the control of T7 promoter.
- 10       To express ANV and 6L15 for the purpose of comparison, the PCR-generated gene fragments of ANV and 6L15, respectively, were inserted into the plasmid using the same strategy for *E. coli* expression.

#### *E. coli* expression

- 15       *E. coli* BL21 (DE3) pLysS [(F<sup>-</sup> *ompT hsdS<sub>B</sub>* (r<sub>B</sub><sup>-</sup> m<sub>B</sub><sup>-</sup>) *gal dcm* (DE3) pLysS (*Cam*)<sup>R</sup>)] (Novagene, Madison, WI) was used for expression of recombinant proteins. *E. coli* DH5α [(F<sup>-</sup> (80d *lacZΔM15*) Δ(*lacZYA-argF*)U169 *endA1 recA1 hsdR17*(r<sub>K</sub><sup>-</sup> m<sub>K</sub><sup>+</sup>) *deoR thi-1 supE44 gyrA96 relA1 λ*)] was used for construction of expression plasmids. The expression plasmid was propagated and isolated from *E. coli* DH5α and was transformed
- 20       into the frozen competent cells of *E. coli* BL21. A single colony was inoculated into a 25-ml LB broth (containing 100 mg/L ampicillin and 34 mg/L chloroamphenicol), and grown overnight at 37° with vigorous shaking. Ten ml of the overnight culture was inoculated into 1 liter of the same medium in a 2.8L flask (Nalgene) and maintained at 37° until the OD<sub>600</sub> of the culture reached 0.5. The culture was induced by adding IPTG (Promega) to a
- 25       final concentration of 1 mM and continuously shaking at 37° for 4 hours. The *E. coli* cells were harvested by centrifugation at 7000 rpm for 12 min. The cell pellet was frozen at -80° for further use.

#### *Construction of Yeast expression plasmid*

- 30       The *Pichia* expression vector of pPIC9, utilizes the strong and highly inducible P<sub>AOXI</sub> promoter and α-factor signal peptide for high level expression and secretion of target

proteins. The fragment containing the gene of interest was cloned in frame with the secretion signal peptide flanked by *Xho* I and *Not* I sites, the sequences from the *Xho* I site to the initiation codon of the target gene encoding the protease site of KEX2 must be created for occurrence of efficient cleavage of the fusion protein. The primers designed for

5 generating PCR fragment of interest for cloning into vector pPIC9 were ANV-xho (5'-CCG CTCGAG AAA AGA GCA CAG GTT CTC AGA G-3') (SEQ ID NO: 38), K<sub>APP</sub>-not (5'-ATA AGA AT GCGGCCGC TTA AAT AGC AGA ACC AC-3') (SEQ ID NO: 39), ANV-ecov (5'-CGC GAT ATC ATC TTC TCC AGC GAG-3') (SEQ ID NO: 40), 5'-K<sub>APP</sub> (5'-GAG GTT TGT TCT GAG CAA GC-3') (SEQ ID NO: 41). The sequences

10 CTCGAG and GCGGCCGC are *Xho* I and *Not* I restriction enzyme sites, respectively, used for editing the gene fragment and ligating into the vector pPIC9. The CTC GAG AAA AGA encoded 4 amino acids, Leu-Glu-Lys-Arg, which is a typical cleavage site for KEX 2 protease, so the following codon in the primer was designed to be the first codon (shown in enlarged text) of the secreted protein of interest. For generating the ANV-K<sub>APP</sub>

15 fusion gene, we designed primer ANV-ecov which would create *EcoRV* site (GATATC) located at 3'-end of the ANV gene fragment without changing the last encoded amino acid (Asp). 5'-K<sub>APP</sub> primer is a forward sequence of K<sub>APP</sub> gene from the initiation codon of Glu (GAG). The K<sub>APP</sub> gene fragment amplified by primers 5'-K<sub>APP</sub> and K<sub>APP</sub>-not was blunt-end ligated to ANV gene amplified by primers ANV-xho and ANV-ecov and digested by

20 *EcoRV* to generate the fusion gene of ANV-K<sub>APP</sub>. The fusion gene was digested by *Xho* I and *Not* I restriction enzymes and ligated to the pPIC9, which was linearized using the same enzymes. The ligation mixture was transformed into *E. coli* DH5 $\alpha$  and the desired clone was screened by PCR and confirmed by DNA sequence analysis to identify the in frame amino acid sequence along with  $\alpha$ -factor signal peptide. The resulting plasmid was

25 pPIC9 ANV-K<sub>APP</sub>.

### *Pichia* expression

The yeast expression plasmid was propagated and isolated from *E. coli* DH5 $\alpha$ . Integration was targeted by digesting the expression plasmid with *Sac* I restriction enzyme

30 prior to transformation. The  $\alpha$ -factor fused gene cassette including *His4* as the selection marker was inserted into the genome of *P. pastoris* GS115 (*his4*) at the *AOX1* locus via electroporation (37). The recombinant strains were selected by growing from the MD (minimal dextrose medium, 1.34 % yeast nitrogen base without amino acid-4x10<sup>-5</sup> %

biotin-2 % dextrose-1.5 % bacto-agar) plate through the *His4* compensation.

A single colony of *P. pastoris* GS115 recombinant strain from the MD plate was inoculated into 2 ml of BMGY medium (buffered glycerol complex medium, 1 % yeast extract-2 % peptone-100 mM potassium phosphate, pH 6.0-1.34 % yeast nitrogen base without amino acid- $4 \times 10^{-5}$  % biotin-1 % glycerol) in 10 cm long Pyrex tube and grown at 30° with vigorous shaking at 200 rpm overnight until the OD<sub>600</sub> of the culture reached 2-6. One ml of culture was harvested by centrifugation and resuspended into 3 ml of BMMY medium (buffered methanol complex medium, 1 % yeast extract-2 % peptone-100 mM potassium phosphate, pH 6.0-1.34 % yeast nitrogen base without amino acid- $4 \times 10^{-5}$  % biotin-0.5 % methanol) in 15 cm long Pyrex tube. The culture was maintained at 30° with vigorous shaking at 200 rpm for 24 hours for expression of the secreted protein. The cells were concentrated by centrifugation at 12,000 rpm for 10 minutes and the supernatant was assayed for inhibitory activity against trypsin. Ten µl of the supernatant was subjected to 12 % SDS-PAGE and the expressed ANV-K<sub>app</sub> was detected by Western blot.

For large-Scale Expression of ANV-K<sub>app</sub> in *Pichia*, a single colony of *P. pastoris* GS115 recombinant strain from the fresh MD plate was inoculated into 25 ml BMGY medium in a 300-ml flask and was grown at 30° with vigorous shaking at 200 rpm for 2 days. This late log phase culture was used to inoculate 400 ml fresh BMGY medium to a final OD<sub>600</sub> of 0.1 in 1 L flask. The culture was maintained at 30° until OD<sub>600</sub> reached 2. The cells were collected by centrifugation at 3000 rpm for 10 minutes in sterilized bottles and resuspended into 1 L of BMMY medium and transferred into 2.8 L flask. The culture was maintained at 30° with shaking to start induction of protein. After 24 hours of induction, the cells were removed by centrifugation and the supernatant was frozen at -80°.

#### Isolation of inclusion bodies from *E. coli*

Frozen *E. coli* cell paste was resuspended in cold Milli-Q water at a concentration of 75 mg/ml. The cells were dispersed with a homogenizer for 30min on ice. The cells were then mechanically lysed by sonication. Lysate was centrifuged at 16,000g for 20min. The supernatant was discarded. The inclusion body pellets were collected, resuspended in the same volume of cold Milli-Q water, homogenized, sonicated, and pelleted by centrifugation as above one more time. The inclusion bodies were stored at -80°.

### *Sulfonation of inclusion bodies and anion exchange chromatography*

The buffers used for sulfonation, anion exchange chromatography, and protein refolding contained high concentration of urea. Urea solutions were treated with Bio Rad mixed bed resin AG®501-X8 at room temperature for at least 20 min and filtered through  
5 0.2 µm filter before mixing with buffers. One gram of inclusion bodies (wet weight) was dispersed in 40ml of a solution containing 50mM Tris/HCl, pH 8.0, and 7.5 M urea by homogenization and vortexing. After the inclusion bodies were largely dissolved, 800mg of sodium sulfide was added, and the mixture was shaken at room temperature for 30min. Then, 400 mg of sodium tetracyanate was added and the mixture was shaken at 4°  
10 overnight. The solution was dialyzed against 400ml of a solution containing 20mM Tris/HCl, pH 8, and 4 M urea. The dialyzed solution was centrifuged at 48,000xg for 1h, filtered through a 0.2 µm filter, and stored at -80°. For anion exchange chromatography, 40 ml of sulfonated and dialyzed sample was loaded onto a HiLoad Q-Sepaharose 16/10 column pre-equilibrated in Q-buffer (20 mM Tris/HCl, pH 8-6 M urea-0.01% Brij 35)  
15 containing 0.15 M NaCl at room temperature. The column was washed with 240ml of equilibration buffer and then eluted with a 396-ml gradient (0.15-0.4 M NaCl) in Q-buffer at a flow rate of 3 ml/min. Nine ml fractions were collected. The peak fractions containing the wanted protein was analyzed by SDS-PAGE, pooled, and used for refolding.

### *20 Refold of disulfide-containing proteins*

A standard refold condition developed for refolding of *E. coli*-derived TFPI as described previously (34) was used for refolding of Kunitz inhibitors and ANV:KPI fusion proteins. In brief, the sulfonated and anion exchange chromatography pool was diluted to an absorbance of 0.07 at 280nm with Q-buffer containing 0.3 M NaCl. Solid L-cysteine  
25 was added to final concentration of 2 mM. The solution was incubated at room temperature for 24 h, diluted 1:1 with water with addition of 1 mM L-cysteine, and incubated at room temperature for another 24-48 h. For single-domain Kunitz proteins, refold can be carried out at a higher protein concentration (absorbance of 0.15 at 280nm) with essentially the same results.



*Purification of 6L15 and ANV-KK<sub>TFPI</sub>*

Refold mixture of 6L15 (18ml) was acidified to pH 3.0 by titrating with 1 M citric acid, diluted 1:1 with water, and passed thorough a 1x8cm Q-Sepharose (fast flow) column pre-equilibrated in 20 mM Na-citrate, pH 3.0. The column was then eluted with a gradient  
5 from 0.1 to 1 M NaCl in the same buffer. 6L15 was eluted as a symmetrical peak around 0.5 M NaCl.

Refold mixture of ANV-KK<sub>TFPI</sub> (600ml) was diluted 1:1 with water and passed through a 1x8cm Q-Sepharose (fast flow) pre-equilibrated with 5 mM Tris, pH 8.0-75 mM NaCl. The column was washed with 50ml of the equilibration buffer. ANV-KK<sub>TFPI</sub> was  
10 then eluted with 5 mM Tris, pH 8.0-0.25 M NaCl.

*Purification of TAP-ANV, ANV-6L15, ANV, and ANV-K<sub>APP</sub>*

Refold mixture of TAP-ANV (160ml) was passed though a 1x8cm Q-Sepharose (fast flow) column pre-equilibrated in 20 mM Tris, 7.4. The column was washed with 50ml of  
15 the same buffer containing 0.15 M NaCl, and eluted with a gradient from 0.15 M to 0.35 M NaCl in the same buffer. TAP-ANV was eluted as a single symmetrical peak around 0.33 M NaCl. Refold mixture of ANV-6L15 was loaded on a 1x8cm Q-Sepharose (fast flow) column pre-equilibrated in 6.7 mM Tris, pH 9.5-2 M urea-0.003 % Brij35-0.1 M NaCl. The column was washed with 40ml of the same buffer, followed by 30ml of 20mM Tris,  
20 pH 7.4, then eluted with a 180ml-gradient from 0.1 M to 1 M NaCl in 20 mM Tris, pH 7.4. ANV-6L15 was eluted at around 0.28 M NaCl. The Q-Sepharose purified TAP-ANV and ANV-6L15 were further purified by adsorption to PS-containing liposomes by modification of the method described by Thiagarajan and Benedict (38). Multilamellar liposomes were prepared according to the method of Kinsky (39). Bovine brain extract  
25 (100 mg) containing 50% PS, 150mg cholesterol, and 10 mg diacetylphosphosphate were dissolved in chloroform and dried in a stream of nitrogen in a 40-ml glass vial. TBS (10 ml) was added to the vial and agitated vigorously in a vortex mixer for 5 min. The liposome was pelleted by centrifugation at 10,000g for 10min. The Q-Sepharose-purified TAP-ANV or ANV-6L15 was added to the liposome and CaCl<sub>2</sub> was added to a final  
30 concentration of 5 mM. The mixture was incubated at room temperature for 40 min, and then centrifuged at 10,000g for 10min. The pellet was washed with TBS-5 mM CaCl<sub>2</sub> was added to a final four times by repeating centrifugation and re-suspension cycle as above. TAP-ANV or ANV-

6L15 was eluted from the liposome using a solution containing 10 mM Tris, pH8.0-5 mM EDTA.

Recombinant ANV was directly isolated from *E. coli* lysate by binding to liposomes as described before (38) with some modification. In brief, the *E. coli* pellet was suspended in 50 mM Tris, pH 7.4-10 mM EDTA, and sonicated on ice to obtain lysate. The lysate was stored at  $-80^{\circ}$ . Aliquot of the lysate was thawed, dialyzed against TBS, and clarified by centrifugation at 15,000g for 30min. The lysate was incubated with liposome in the presence of 5 mM  $\text{CaCl}_2$  for 40min, followed by washing, centrifugation, and EDTA-elution as described above.

Recombinant ANV- $\text{K}_{\text{APP}}$  was expressed and secrete into the culture medium of *pichia*. The medium was concentrated about 10 fold, exchanged with a buffer containing 10 mM Tris, pH 7.4-0.15 M NaCl, and clarified by centrifugation at 40,000g for 1h. The medium concentrate was incubated with liposome in the presence of 5 mM  $\text{CaCl}_2$ , followed by washing, centrifugation, and EDTA-elution as described above. All the proteins eluted from liposomes by EDTA solution were subjected to centrifugation at 20,000g for 1h to separate the proteins from majority of the liposomes. To remove residual vesicles, the protein solutions were further filtered through CentriPlus YM-100 (Amicon).

#### ***Protein determination***

The concentrations of proteins were determined by absorbance at 280nm using theoretical extinction coefficients calculated from amino acid sequence data as described by Gill and von Hippel (40). The following molar extinction coefficients were used: ANV (21,050); TAP-ANV (39,550); ANV-6L15 (28,170); ANV- $\text{K}_{\text{APP}}$  (31,300); ANV-KK- $\text{TFPI}$  (30,170); TAP (18,500); 6L15 (7,120); C127- and *E. coli*-derived FL-TFPI (20,650); C127 truncated TFPI (19,370); TFPI-160 (7,840); X-K1 (14,490).

#### ***Amidolytic assays of trypsin and factor Xa inhibitory activities: Determination of stoichiometries of inhibitor-protease interactions***

Bovine factor Xa (from American Diagnostica) and porcine trypsin (from Sigma) were titrated with *p*-nitrophenyl *p*'-guanidinobenzoate according to Smith (41) and Chase and Shaw (42), respectively, to determine the concentrations of active factor Xa and

trypsin. Inhibitory activities of TAP, TAP-ANV, and ANV-KK- $\text{TFPI}$  against factor Xa were assayed by amidolysis of S2765. Ten  $\mu\text{l}$  of 50 nM bovine factor Xa in DB-buffer (10 mM Tris, pH 7.5-0.15 M NaCl-1mg/ml BSA-0.002% Tween 20-0.02 %  $\text{NaN}_3$ ) was mixed with 10  $\mu\text{l}$  inhibitors diluted in the same buffer. After incubation at room temperature for 30 min, 10  $\mu\text{l}$  of the reaction mixture was taken into 96-well plate and mixed with 85  $\mu\text{l}$  of TBS-buffer (50mM Tris, pH 7.5-0.15 M NaCl-0.02%  $\text{NaN}_3$ ) containing 5 mM  $\text{CaCl}_2$ . The absorbance change at 405nm was recorded on SPECTRAMax<sup>®</sup> PLUS<sup>384</sup> (Molecular Devices, Sunnyvale, CA) microplate spectrophotometer at room temperature for 60 sec. Stock solution of porcine trypsin was prepared in 50% glycerol-1 mM HCl-20 mM  $\text{CaCl}_2$  and stored at  $-20^\circ$ . Inhibitory activities of 6L15, ANV-6-L15, and ANV-K<sub>APP</sub> against trypsin were assayed by amidolysis of S2444. A diluted trypsin solution (23nM) was freshly prepared from the stock in a buffer containing TBS-0.1 mg/ml BSA-20 mM  $\text{CaCl}_2$ . Ten  $\mu\text{l}$  of the trypsin solution was mixed with 10  $\mu\text{l}$  of inhibitors diluted in the same buffer in the microplate well. After incubation at room temperature for 10min, 75  $\mu\text{l}$  of TBS-20 mM  $\text{CaCl}_2$  and 5 $\mu\text{l}$  of 10mM S2444 was added to the mixture and the absorbance change at 405nm was recorded on the microplate spectrophotometer at room temperature for 2min. In both assays, the fractional activities in the presence of inhibitors were calculated as percentages of that in the absence of inhibitors.

#### 20 *Plasma clotting time assays*

Human plasma clotting assays were carried out on an ACL 200 coagulation analyzer (Instrumentation Laboratory, Lexington MA). A pooled normal plasma from 4 donors was used. For tissue factor-induced plasma clotting assay, each sample contains 100  $\mu\text{l}$  of pooled plasma mixed with equal volume of an inhibitor dissolved in DB-buffer (10 mM Tris, pH 7.4-0.15 M NaCl-1 mg/ml BSA- 0.02%  $\text{NaN}_3$ ) at varying concentrations. Inhibitor concentrations were calculated as nanomolar in plasma alone, not final plasma-buffer mixture. Innovin<sup>®</sup> (recombinant human tissue factor reconstituted with synthetic phospholipids) was diluted 1:100 with PT-buffer (75 mM NaCl-12.5 mM  $\text{CaCl}_2$ -0.5 mg/ml BSA-0.02 %  $\text{NaN}_3$ ) for the assay. For activated partial thromboplastin time (APTT) assay, each sample contains 180  $\mu\text{l}$  of pooled plasma mixed with 20 $\mu\text{l}$  of an inhibitor dissolved in DB-buffer at varying concentrations. Inhibitor concentrations were calculated as the final concentration in the plasma-buffer mixtures. APTT-SP reagent (Instrumentation

Laboratory) was used for the assay without dilution.

## Results

### *Construction and expression of recombinant ANV and ANV:KPI fusions*

Plasmid vectors were constructed and used for expression of recombinant ANV and its fusion proteins with various Kunitz-type protease inhibitors possessing specific inhibitory activities against four key coagulation enzymes, factor VIIa, factor IXa, factor Xa, and factor XIa in the clotting cascade. Fig. 2. schematically depicts the molecular structures of these proteins. ANV was expressed as a full-length un-mutated molecule in *E. coli*. For other ANV-KPI fusions, the Cys<sup>315</sup> of ANV was mutated to Ala to avoid forming disulfide bonds with the cysteines within the Kunitz domains during protein refolding. The fusion protein of TAP-ANV is total of 382 amino acid residues starting with an Ala residue followed by a 60 amino acids of TAP from Tyr<sup>1</sup> to Ile<sup>60</sup>, a dipeptide Gly-Ser, and a 319 amino acids of ANV(Cys<sup>315</sup>-to-Ala). The fusion protein of ANV-6L15 is total of 378 amino acid residues with a 319 amino acids of ANV(Cys<sup>315</sup>-to-Ala) from initial Ala to the final amino acid (Asp) followed by a 60 amino acids of 6L15 from Met<sup>1</sup> to Ala<sup>60</sup>. In order to create the *NsiI* restriction enzyme site for gene editing and ligation, the second amino acid of 6L15 in the fusion protein was changed from Ala to His. The fusion protein of ANV-K<sub>APP</sub> is a polypeptide of 376 amino acids in total length. The N-terminus is the full length ANV(Cys<sup>315</sup>-to-Ala) and the C-terminus is a 57 amino acids of K<sub>APP</sub> polypeptide from Asp<sup>1</sup> to Ile<sup>57</sup>. The fusion protein of ANV-KK<sub>TFPI</sub> is a polypeptide of 459 amino acid residues in length. The N-terminus of this fusion protein is a full length ANV(Cys<sup>315</sup>-to-Ala) fused with a 140 amino acid polypeptide starting from Met<sup>22</sup> to Thr<sup>161</sup> of TFPI protein, including Kunitz domains 1 and 2.

25

### *Purification of ANV and ANV:KPI fusion proteins*

Recombinant ANV, TAP-ANV, ANV-6L15, and ANV-KK<sub>TFPI</sub> were expressed intracellularly in *E. coli*. Essentially all the ANV molecules present in the *E. coli* lysate were capable of binding to PS-containing liposomes in the presence of Ca<sup>2+</sup> when analyzed by SDS-PAGE, suggesting that the expressed protein spontaneously folded itself into active forms. For other *E. coli*-expressed ANV:KPI fusions, majority of the expressed proteins occurred in inclusion bodies and required refolding to obtain active molecules.

30

Using a sulfonation refold process developed previously for TFPI (34), we were able to achieve refolding of ANV:KPI fusion proteins as evidenced from the increase in inhibitory activity against trypsin or factor Xa during refolding. One-step Q-Sepharose chromatography of a refold mixture achieved high degree of purification as a single major band with the expected apparent molecular mass was observed in SDS-PAGE analysis. Further purification was carried out by binding to PS-containing liposomes in the presence of  $\text{Ca}^{++}$  followed by elution with EDTA. Recombinant ANV-K<sub>APP</sub> was expressed and secreted into the culture medium of *P. pastoris* in active form. Active ANV-K<sub>APP</sub> can be purified from concentrated medium by binding to PS-containing liposome in the presence of  $\text{Ca}^{++}$  and elution with EDTA. SDS-PAGE analysis of the final purified products is shown in Fig. 3. Under non-reducing condition (Fig. 3A), a major band was seen in each preparation. ANV-KK<sub>TFPI</sub> (lane 2) and ANV (lane 6) both contained traces of dimmers. Under reducing condition (Figure 3B), the dimers disappeared and the fusion protein bands migrated slightly slower possibly because of disruption of disulfide bonds and unfolding of the Kunitz domains.

#### *Stoichiometries of the interaction of the purified inhibitors with trypsin or factor Xa*

Fig. 4 shows the titrations of trypsin or factor Xa activities by the purified inhibitors. Except ANV-KK<sub>TFPI</sub>, the purified fusion inhibitors (ANV-6L15, TAP-ANV, and ANV-K<sub>APP</sub>) and the Kunitz inhibitors (6L15 and TAP) all inhibits trypsin or factor Xa with apparent stoichiometries of 1:1. These results indicated that all the purified inhibitors containing a single Kunitz domain were substantially pure and fully active. The extent of deviation from 1:1 stoichiometry observed near equimolar concentration of inhibitor and enzyme reflects the variation in affinity of the interactions. The affinities of ANV-6L15, 6L15, and ANV-K<sub>APP</sub> for trypsin (Fig 4 A, B, and E) appear stronger and the associations of TAP-ANV and TAP with factor Xa (Fig. 4C, and D) appear weaker. Evidence of weaker affinities of TAP-ANV and TAP with factor Xa are also inferred from time-dependent slow increases of amidolytic activity upon addition of substrate and buffer in the assay. Titration of Xa with ANV-KK<sub>TFPI</sub> showed deviation from 1:1 stoichiometry (Fig. 4F). This is possibly due to the weak binding affinity of TFPI-K2 for Xa ( $K_i=90$  nM) (43), thus the stoichiometry of interaction cannot be determined under the experimental condition used. Alternatively, the purified ANV-KK<sub>TFPI</sub> may contain inactive misfolded species.

### *Prolongation of tissue factor-initiated clotting time*

It is well established that TF is the physiologic trigger of blood coagulation. Therefore, the anticoagulant effects of various inhibitors were examined in TF-initiated plasma coagulation assay. Purified inhibitors were added to pooled human plasma at different concentrations and plasma clotting was initiated by adding a diluted thromboplastin reagent (1:100 dilution of Dade Innovin®). Innovin® is a commercial preparation of recombinant human TF reconstituted with an optimized phospholipid mixtures. The assay reagent contains both TF and anionic phospholipid to allow initiation and propagation of the coagulation cascade, and is a simplified system mimicking plasma clotting in the presence of activated TF-bearing cells/microparticles and platelets. The clotting time of the pooled plasma with added control buffer was 40.7 sec. With increasing concentration of added inhibitors, the clotting time was progressively prolonged. The concentration of inhibitors prolonging the clotting time 1.5 fold (i.e. from 40.7 to 61.1 sec) can be determined from the concentration-clotting time curves. Table 1 shows the concentrations required to prolong clotting time 1.5 fold for various inhibitors and their relative potency ranking. Since TFPI is the most important physiological regulator of the tissue factor pathway of coagulation in blood, and mammalian cell-derived TFPI may resemble most the former, we have chosen recombinant C127 FL-TFPI as a reference standard for comparison. TAP-ANV, presumably targeting the prothrombinase, is 86-fold more potent compare to C127 FL-TFPI. ANV-6L15, designed to inhibit TF/VIIa, is 12 fold more potent than C127 FL-TFPI. ANV-K<sub>APP</sub> (possibly targeting TF/VIIa, XIa, VIIIa/IXa, and Va/Xa), ANV-KK<sub>TFPI</sub> (presumably inhibiting TF/VIIa and Va/Xa), *E. coli*-derived non-glycosylated TFPI (presumably inhibiting TF/VIIa/Xa), and X-K1<sub>TFPI</sub> hybrid (likely inhibiting TF/VIIa) are 6-7 fold more potent than C127 FL-TFPI. ANV alone is 2.4 fold more potent than C127 FL-TFPI. TAP has the same potency as C127 FL-TFPI. Kunitz inhibitors alone, as exemplified here by TFPI1-160 and 6L15, are 40- and 59-fold, respectively, less active than C127 FL-TFPI.

### *Effects of various inhibitors on APTT*

The anticoagulant effects of various inhibitors were also examined by activated partial thromboplastin time (APTT) assay. APTT measures the intrinsic pathway activity. The effects of various inhibitors in prolonging APTT are shown in Fig. 5. For the purpose of

comparison, ANV is chosen as a reference standard. The most potent molecule, TAP-ANV, is about an order of magnitude more potent than ANV. The effect is likely mediated through inhibition of prothrombinase. ANV-K<sub>APP</sub> (presumably inhibiting XIa, VIIIa/IXa, and Va/Xa), ANV-KK<sub>TFPI</sub> (presumably inhibiting Va/Xa), and ANV-6L15 (possibly inhibiting kallikrein and XIa) are several-fold more potent than ANV. The Kunitz inhibitors alone (6L15, TAP, and TFPI1-160) are very weak in prolonging APTT. Interestingly, glycosylated mammalian C127 FL-TFPI is about an order of magnitude more potent than non-glycosylated *E. coli*-derived TFPI (Fig 5), the order of potency being reversed vs. that of tissue factor-induced clotting (Table 1). These results suggest that there are significant differences between mammalian- and *E. coli*-derived TFPIs.

**Table 1:**

Effects of various inhibitors on tissue factor-induced clotting time in human plasma.

Inhibitor	<sup>a</sup> [Inhibitor] <sub>1.5CT</sub> (nM)	<sup>b</sup> Relative potency
TAP-ANV	0.80	86
ANV-6L15	6.0	12
ANV-K <sub>APP</sub>	9.4	7.3
X-K1 <sub>TFPI</sub>	10	6.9
ANV-KK <sub>TFPI22-160</sub>	11	6.3
<i>E. coli</i> ala-TFPI	19	6.3
ANV	29	2.4
TAP	68	1
C127 FL-TFPI <sup>c</sup>	69	1
C127 CT-TFPI <sup>c</sup>	1300	0.053
<i>E. coli</i> TFPI1-160	2750	0.025
6L15	5900	0.017

<sup>a</sup> [Inhibitor]<sub>1.5CT</sub> is the concentration of inhibitor that prolong the tissue factor-induced clotting time 1.5 fold relative to control (from 40.7 to 61.1sec) as determined from concentration-dependent clotting time curves for each inhibitor.

<sup>b</sup> Relative potency is calculated from [Inhibitor]<sub>1.5CT</sub> using mammalian C127 FL-TFPI as reference standard (assigning C127 FL-TFPI as 1).

<sup>c</sup> C127 FL-TFPI refers to full-length molecules; CT-TFPI refers to molecules truncated at the carboxyl terminus as described previously (33).

Although the inventor is not to be bound by theory, it is believed that the foregoing results can be explained and elaborated thereon as follows:

Formation of extrinsic tenase (TF/VIIa), intrinsic tenase (VIIIa/IXa), prothrombinase (Va/Xa) and XIa enzymatic complexes on anionic membrane surfaces are the key processes by which initiation and propagation of the tissue factor pathway of coagulation occur. TFPI is the primary physiological regulator of the initiation of coagulation. TFPI does not directly inhibit TF/VIIa complex per se, but in stead, must await generation of factor Xa first before forming an inert quartnary TFPI/Xa /TF/VIIa complex (17). Generation of factor Xa leads to formation of prothrombinase (Va/Xa), and once formed, prothrombinase is protected from inactivation by physiological concentration of TFPI (44,45). During this process, some intrinsic tenase (VIIIa/IXa) is also generated which is not inhibited by TFPI. As a result, TFPI regulates tissue factor pathway in a rather "leaky" manner. In *in vitro* clotting assay using 1:100 dilution of a commercial thromboplastin reagent, it requires 69 nM of mammalian cell-derived full-length TFPI to prolong clotting time just 1.5 fold (Table 1). In *in vivo* thrombosis models, efficacies were observed only when high concentrations of TFPI (100-200 nM) are present in circulating blood or topically (18,19,46). These therapeutic doses of TFPI represent about 100-200 fold of that in the normal plasma. The apparent low potency and the large infusion dose required to achieve the desired blood level make TFPI less than ideal for therapeutic applications. Hence, it is highly desirable to have alternative molecules that exert better control of the tissue factor pathway of coagulation. The ANV:KPI fusion proteins created herein are far more potent than TFPI in the inhibition of TF-initiated coagulation and possess other advantages over TFPI as therapeutic anticoagulants.

Coagulation cascade reactions are localized on PS-exposed membrane surfaces that facilitate the assembly of the coagulation complexes and enhance the catalytic efficiency. In the present work, it is hypothesized that enzyme inhibitors that have been conferred the ability to target themselves to the PS-exposed membrane surface would become thrombogenic site-specific and more effective in inhibiting the coagulation complexes. To test this hypothesis, recombinant DNA technology is used to create four fusion proteins that share a common ANV domain linking to different KPI domains (TAP, 6L15, K<sub>APP</sub>, and KK<sub>TFPI</sub>). The ANV moiety has high affinity ( $K_d < 0.1$  nM) for membranes containing PS (32). The four KPIs chosen for this study have the following inhibition constants ( $K_i$ ) for various coagulation serine proteases: TAP (0.18 nM for Xa) (22); 6L15 (0.2 nM for



TF/VIIa, 0.02 nM for plasma kallikrein and 13 nM for XIa) (30,31); K<sub>APP</sub> (68 nM for TF<sub>219</sub>/VIIa; 13 nM for Xa; 190 nM for IXa; and 0.01 nM for XIa.) (24-27); and K1K2<sub>TFPI</sub> (90 nM for Xa and 240 nM for TF/VIIa) (43). Based on the specificities of these KPIs, the fusion proteins are presumed to preferentially target various membrane-associated

5 coagulation enzyme complexes as follows: TAP-ANV for Va/Xa; 6L15-ANV for TF/VIIa, kallikrein, and XIa; K<sub>APP</sub> for XIa, Va/Xa, TF/VIIa, and VIIIa/IXa; and ANV-KK<sub>TFPI</sub> for Va/Xa and TF/VIIa. *In vitro* clotting assays, the KPIs all require fairly high concentrations in plasma to prolong clotting times (30, 47, Table 1 and Figure 5). All the four ANV:KPI fusion proteins, in contrast, prolong the plasma clotting times at greatly

10 reduced concentrations compared to their component ANV and KPIs (Table 1 and Fig. 5). In both TF-induced plasma clotting and APTT assays, the most potent fusion protein is TAP-ANV. This molecule inhibits prothrombinase since TAP is a highly specific inhibitor of factor Xa. The result is consistent with the finding that factor Xa and prothrombinase generation is the rate-limiting step in the coagulation cascade (3). It is significant to note

15 that 6L15 is a very poor inhibitor of TF-initiated plasma clotting (Table 1) in spite of its high affinity binding with TF/VIIa (K<sub>d</sub> 0.2 nM) (30). Thus, high affinity binding of TF/VIIa alone does not correlate with good potency in inhibiting TF-initiated clotting cascade. In contrast, the fusion inhibitor of ANV-6L15 is about three-order of magnitude more potent than 6L15 in inhibiting TF-initiated clotting, indicating that binding to PS

20 greatly facilitates the inhibition of TF/VIIa by 6L15. The four ANV:KPI fusion molecules created herein all show much higher anticoagulant activities than ANV, KPIs, and TFPI as assessed by TF-initiated plasma clotting and APTT assays. Thus, these molecules possess superior anticoagulant potencies to those of the natural anticoagulants.

*In vivo* animal study has demonstrated that ANV can specifically target and

25 accumulate on platelet-containing thrombi (48). Furthermore, ANV preferentially accumulates at sites of vessel injury and dose-dependently inhibits thrombus formation in arterial and venous thrombosis models (38,49,50). An important attribute of the ANV:KPI fusion proteins described herein is the presence of ANV moiety that confers on them the property of binding specifically to PS with high affinity. Thus, these molecules possess an

30 intrinsic property of targeting themselves to sites of thrombus formation where PS becomes available for assembly of coagulation complexes. Owing to their ability to target thrombogenic sites, it will be feasible to achieve antithrombotic effect without maintaining high levels of these anticoagulants in systemic circulation, thereby minimizing risks of

systemic bleeding side effect.

As used herein, the term "pharmaceutically acceptable" refers to a characteristic of carriers, excipients, or other additives commonly used to formulate drug compositions for administration to subjects for the treatment of diseases and conditions.

- 5 As used herein the term "subject" refers to both a human or an animal having or suspected of an excess of thrombotic activity.

- The terms "effective" and "therapeutically effective" as used herein refer to a characteristic of an amount of a therapeutic compound or composition, wherein when administered to a subject, the amount achieves one or more of the goals of preventing, inhibiting, reducing or eliminating a disease or condition being treated in the subject. With respect to the present application, diseases and conditions amenable to treatment according to the methods and materials provided, include any disease or condition involving an excess of thrombogenesis. Such diseases and conditions include, for example, unstable angina, myocardial infarction, sudden cardiac death, ischemic stroke, ruptured aneurisms, intermittent claudication, critical limb ischemia; deep venous thrombosis, pulmonary embolism, thrombophlebitis, chronic venous insufficiency; surgical thrombosis, prosthetic heart valve, atherosclerosis, restenosis, ischemia reperfusion injury, sepsis, disseminated intravascular coagulation, acute lung injury, malignancy, chronic renal failure, nephrotic syndrome, crescentic glomerulonephritis, diabetes, sickle cell disease, thalassemia, antiphospholipid syndrome, extra-corporeal circulation, hemodialysis, peritoneal dialysis, and annexinopathies.
- 10  
15  
20

- The terms "dosing" and "treatment" as used herein refer to any process, action, application, therapy or the like, wherein a subject, particularly a human being, is rendered medical aid with the object of improving the subject's condition, either directly or indirectly.
- 25

The term "therapeutic compound" as used herein refers to a compound useful in the prophylaxis or treatment of a thrombogenesis-related disease or condition.

- As demonstrated herein, this series of recombinant proteins can be produced in *E. coli* and yeast. In the *E. coli* system, the proteins can be expressed at very high levels in the inclusion bodies, and active molecules can be obtained by simple refold and purification procedures. In the *Pichia* system, the protein can be secreted into the culture medium in active form and purified by the same simple procedure. From a manufacturing
- 30

standpoint, ease and low cost of production are of great advantage. However, it is contemplated that other prokaryotic and eukaryotic cell lines can be used as according to well known general molecular biology procedures as described in, for example, in Sambrook, et al., MOLECULAR CLONING--A LABORATORY MANUAL, Second Edition, (Cold Spring Harbor Laboratory, 1989).

Based on the results of the present work, it is believed that other fusion molecules of similar conceptual design can be created. For example: fusion proteins consisting of multiple ANV domains or KPI domains; fusions of ANV with other natural inhibitors of coagulation factors, such as Antistasin, ecotin (51), Acylostoma caninum anticoagulant peptides; fusions of ANV with homologs and variants of KPIs; and fusions of ANV with small-molecule inhibitors of factors VIIa, IXa, Xa, and XIa. In another variation, other PS binding proteins such as other members of annexin family, lacadherin (52), and phospholipid binding moieties of factor V, factor VIII and phospholipase A<sub>2</sub> can be used in place of ANV for the creation of fusion molecules. In a further example, disintegrin domains can be linked to ANV or ANV-KPIs to create fusion molecules that inhibit both coagulation reactions and platelet aggregation at sites of thrombogenesis.

All such other examples as will be apparent to the person skilled in the art after reading the present disclosure are intended to be included within the scope of the present invention.

In summary, the newly developed ANV:KPI fusion proteins represent a new class of thrombogenic site-targeted anticoagulants with the following characteristics: (a) They are designed to target TF/VIIa, intrinsic tenase (VIIIa/IXa), prothrombinase (Va/Xa) and XIa associated with PS-exposed thrombogenic membranes; (b) They possess 6-86 fold higher anticoagulant potencies than TFPI, the natural inhibitor of coagulation initiation, in TF-initiated coagulation; (c) Ease and low cost of production, because fully active molecules can be produced by microbial systems and purified by simple Ca<sup>++</sup>-dependent binding to PS-containing liposome followed by elution with a Ca<sup>++</sup>-chelating solution; and (d) Because PS-exposed membranes and associated coagulation complexes are key thrombogenic stimuli at vascular lesions, ANV:KPIs are potentially useful antithrombotic drugs capable of localized passivation of thrombogenic vessel walls and associated thrombi.

## References

1. Morrissey JH. Tissue factor: An enzyme cofactor and a true receptor. *Thromb Haemost* 2001; 86: 66-74.
2. Rand MD, Lock JB, van't Veer C, Gaffney DP, Mann KG. Blood clotting in minimally altered whole blood. *Blood* 1996; 88: 3432-45.
3. Mann KG. Biochemistry and physiology of blood coagulation. *Thromb Haemost* 1999; 82: 165-74.
4. Hoffman M, Monroe DM, Oliver JA, Roberts HR. Factors IXa and Xa play distinct roles in tissue factor-dependent initiation of coagulation. *Blood* 1995; 86:1794-801.
5. Monroe DM, Hoffman M, Allen GA, Roberts HR. The factor VII-platelet interplay: effectiveness of recombinant factor VIIa in the treatment of bleeding in severe thrombocytopathia. *Sem Thromb Haemost* 2000; 26: 373-7.
6. Sims PJ, Wiedmer T. Unraveling the mysteries of phospholipid scrambling. *Thromb Haemost* 2001; 86: 266-75.
7. Zwaal RFA, Comfurius P, Bevers EM. Lipid-protein interactions in blood coagulation. *Biochim Biophys Acta* 1998; 1376: 433-53.
8. Zwaal RFA, Schroit AJ. Pathophysiological implications of membrane phospholipid asymmetry in blood cells. *Blood* 1997; 89: 1121-32.
9. Dachary-Prigent J, Toti F, Satta N, Pasquet J-M, Uzan A, Freyssinet J-M. Physiopathological significance of catalytic phospholipids in the generation of thrombin. *Sem Thromb Hemost* 1996; 22: 157-64.
10. Bach R, Rifkin DB. Expression of tissue factor procoagulant activity: Regulation by cytosolic calcium. *Proc Natl Acad Sci USA* 1990; 87: 6995-9.
11. Le DT, Rapaport SI, Rao LVM. Studies of the mechanism for enhanced cell surface factor VIIa/tissue factor activation of factor X on fibroblast monolayers after their exposure to N-ethylmaleimide. *Thromb Haemost* 1994; 72: 848-55.
12. Hansen CB, van Deurs B, Petersen LC, Rao LVM. Discordant expression of tissue factor and its activity in polarized epithelial cells. Asymmetry in anionic phospholipid availability as a possible explanation. *Blood* 1999; 94: 1657-64.
13. Greeno EW, Bach R, Moldow CF. Apoptosis is associated with increased cell surface tissue factor procoagulant activity. *Lab Invest* 1996; 75: 281-9.
14. Bombeli T, Karsan A, Tait JF, Harlan JM. Apoptotic vascular endothelial cells become procoagulant. *Blood* 1997; 89: 2429-42.
15. Krishnaswamy S, Field KA, Edgington TS, Morrissey JH, Mann KG. Role of the membrane surface in the activation of human coagulation factor X. *J Biol Chem* 1992; 267: 26110-20.
16. Bevers EM, Comfurius P, VanRijn JLML, Hemker HC, Zwaal RFA. Generation of prothrombin-converting activity and the exposure of phosphatidylserine at the outer surface of platelets. *Eur J Biochem* 1982; 122: 429-36.
17. Broze GJ Jr. Tissue factor pathway inhibitor and the current concept of blood coagulation. *Blood Coagul Fibrinol* 1995; 6: 7-13.
18. Haskel EJ, Torr SR, Day KC, Palmier MO, Wun TC, Sobel BE, Abendschein DR.

- Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. *Circulation* 1991; 84: 821-7.
19. Jang Y, Guzman LA, Linkoff AM, Gottsauner-Wolf M, Forudi F, Hart CE, Courtman DW, Ezban M, Ellis SG, Topol EJ. Influence of blockade at specific levels of the coagulation cascade on restenosis in a rabbit atherosclerotic femoral artery injury model. *Circulation* 1995; 92: 3041-50.
20. Girard TJ. Tissue factor pathway inhibitor. In Sasahara AA, Loscalzo J (eds): *New Therapeutic Agents in Thrombosis and Thrombolysis*. New York, Marcel Dekker, 1997, p 225.
- 10 21. Tuszyński GP, Gasic TB, Gasic GJ. Isolation and characterization of antistasin. *J Biol Chem* 1987; 262: 9718-23.
22. Waxman L, Smith DE, Arcuri KE, Vlasuk GP. Tick anticoagulant peptide is a novel inhibitor of blood coagulation factor Xa. *Science* 1990; 248: 593-6.
23. Stanssen P, Bergum PW, Gansemans Y, Jespers L, Laroche Y, Huang S, Maki S, Messens J, Lauwereys M, Cappello M, Hotez PJ, Lasters I, Vlasuk GP. Anticoagulant repertoire of the hookworm *Ancylostoma caninum*. *Proc Natl Acad Sci USA* 1996; 93: 2149-54.
- 15 24. Mahdi F, Rehmetulla A, Wan Nostrand WE, Bajaj SP, Schmaier AH. Protease nexin-2/amyloid  $\beta$ -protein precursor regulates factor VIIa and the factor VIIa-tissue factor complex. *Thromb Res* 2000; 99: 267-76.
- 20 25. Schmaier AH, Dahl LD, Hasan AAK, Cines DB, Bauer KA, Van Nostrand WE. Factor IXa inhibition by protease nexin-2/amyloid beta-protein precursor on phospholipid vesicles and cell membranes. *Biochemistry* 1995; 34: 1171-8.
26. Mahdi F, Van Nostrand WE, Schmaier AH. Protease nexin-2/amyloid beta-protein precursor inhibits factor Xa in the prothrombinase complex. *J Biol Chem* 1995; 270: 23468-74.
- 25 27. Smith RP, Higuchi DA, Broze GJ Jr. Platelet coagulation factor XIa inhibitor, a form of Alzheimer amyloid precursor protein. *Science* 1990; 248: 1126-8.
28. Dennis MS, Lazarus RA. Kunitz domain inhibitors of tissue factor-factor VIIa. I. Potent inhibitors selected from libraries by phage display. *J Biol Chem* 1994; 269: 22129-36.
- 30 29. Dennis MS, Lazarus RA. Kunitz domain inhibitors of tissue factor-factor VIIa. II. Potent and specific inhibitors by competitive phage selection. *J Biol Chem* 1994; 269: 22137-44.
- 35 30. Stassen JM, Lambeir AM, Matthyssens G, Ripka WC, Nystrom A, Sixma JJ, Vermynen J. Characterization of a novel series of aprotinin-derived anticoagulants. I. *In vitro* and pharmacological properties. *Thromb Haemost* 1995; 74: 646-54.
31. Stassen JM, Lambeir AM, Vreys I, Deckmyn H, Matthyssens G, Nystrom A, Vermynen J. Characterization of a novel series of aprotinin-derived anticoagulants. II. Comparative antithrombotic effects on primary thrombus formation *in vivo*. *Thromb Haemost* 1995; 74: 655-59.
- 40 32. Reutelingsperger CPM, van Heerde WL. Annexin V, the regulator of phosphatidylserine-catalyzed inflammation and coagulation during apoptosis. *Cell Mol Life Sci* 1997; 53: 527-32.

33. Wun TC, Kretzmer KK, Palmier MO, Day KC, Huang MD, Welsch DJ, Lewis C, Wolfe RA, Zobel JF, Lange GW, Frazier RB, Bild GS, Peel MA, Shell RE, Horn NA, Junger KD, Foy BA, Gustafson ME, Leimgruber RM, Novotney WF, Broze GJ Jr, Pyla YE, Hippenmeyer PJ, Warren TG. Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, and Chinese hamster ovary cells. *Thromb Haemost* 1992; 68: 54-9.
- 5
34. Diaz-Collier JA, Palmier MO, Kretzmer KK, Bishop BF, Combs RG, Obukowicz MG, Frazier RB, Bild GS, Joy WD, Hill SR, Duffin KL, Gustafson ME, Junger KD, Grabner RW, Galluppi GR, Wun TC. Refold and characterization of recombinant tissue factor pathway inhibitor expressed in *E. coli*. *Thromb Haemost* 1994; 71: 339-46.
- 10
35. Girard TJ, MacPhail LA, Likert KM, Novotny WF, Miletich JP, Broze GJ Jr. Inhibition of factor VIIa-tissue factor coagulation activity by a hybrid protein. *Science* 1990; 248: 1421-4.
36. Neeper MP, Waxman L, Smith DE, Schulman CA, Sardana M, Ellis RW, Schaffer LW, Siegl PKS, Vlasuk GP. Characterization of recombinant tick anticoagulant peptide: A highly selective inhibitor of blood coagulation factor Xa. *J Biol Chem* 1990; 265: 17746-52.
- 15
37. Scorer CA, Clare JJ, McCombie WR, Romanos MA, and Sreekrishna K. Rapid selection using G418 of high copy number transformants of *Pichia pastoris* for high-level foreign gene expression. *Biotechnology* 1994; 12: 181-4.
- 20
38. Thiagarajan P, Benedict CR. Inhibition of arterial thrombosis by recombinant annexin V in a rabbit carotid artery injury model. *Circulation* 1997; 96: 2339-47.
39. Kinsky SC. Preparation of liposomes and a spectrometric assay for release of trapped glucose marker. *Methods Enzymol.* 1974; 32: 501-514.
- 25
40. Gill SC, von Hippel PH. Calculation of protein extinction coefficients from amino acid sequence data. *Anal Biochem* 1989; 182: 319-26.
41. Smith RL. Titration of activated bovine factor X. *J Biol Chem* 1973; 248: 2418-23.
42. Chase T Jr, Shaw E. Titration of trypsin, plasmin, and thrombin with *p*-nitrophenyl *p*'-guanidinobenzoate HCl. *Methods Enzymol* 1970; 19: 20-7.
- 30
43. Petersen LC, Bjorn SE, Olsen OH, Nordfang O, Norris F, Norris K. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue factor pathway inhibitor. *Eur J Biochem* 1996; 235, 310-6.
44. Mast A, Broze GJ Jr. Physiological concentrations of tissue factor pathway inhibitor do not inhibit prothrombinase. *Blood* 1996; 87: 1845-50.
- 35
45. Franssen J, Salemink I, Willems GM, Wun TC, Hemker C, Lindhout T. Prothrombinase is protected from inactivation by tissue factor pathway inhibitor: competition between prothrombin and inhibitor. *Biochem J* 1997; 323: 33-7.
46. Ozbeck MR, Brown DM, Deune EG, Lantieri LA, Kania NM, Pasia EN, Cooley BC, Wun T-C, Khouri RK. Topical tissue factor pathway inhibitor improves free flap survival in a model simulating free flap errors. *J Reconstr Microsurg* 1995; 11: 185-188.
- 40
47. Schmaier AH, Dahl LD, Rozemuller AJM, Roos RAC, Wagner SL, Chung R, Van Nostrand WE. Protease Nexin-2/Amyloid  $\beta$  protein precursor. A tight-binding inhibitor of coagulation factor IXa. *J Clin Invest* 1993; 2540-5.

48. Tait JF, Cerqueira MD, Dewhurst TA, Fujikawa K, Ritchie JL, Stratton JR. Evaluation of annexin V as a platelet-directed thrombus targeting agent. *Thromb Res* 1994; 75: 491-501.
49. Romisch J, Seiffge D, Reiner G, Paques EP, Heimburger N. *In vivo* antithrombotic potency of placenta protein 4 (annexin V). *Thromb Res* 1991; 61: 93-104.
50. Van Ryn McKenna J, Merk H, Muller TH, Buchanan MR, Eisert WG. The effect of heparin and annexin V on fibrin accretion after injury in the jugular vein of rabbit. *Thromb Haemost* 1993; 69: 227-30.
51. McGrath ME, Gillmor SA, Fletterick RJ. Ecotin: lessons on survival in a protease-filled world. *Protein Sci* 1995; 4:141-8.
52. Shi J, Gilbert GE. Lactadherin inhibits enzyme complexes of blood coagulation by competing for phospholipid-binding sites. *Blood* 2003; 101:2628-36.

## CLAIMS

1. A recombinant anticoagulant protein comprising a fusion of annexin V (ANV) (SEQ ID NO: 10) and a Kunitz protease inhibitor (KPI).
2. A recombinant anticoagulant protein according to Claim 1 comprising a protein  
5 sequence selected from the group consisting of TAP-ANV (SEQ ID NO: 1), ANV-6L15 (SEQ ID NO: 2), ANV-K<sub>APP</sub> (SEQ ID NO: 3), and ANV-KK<sub>TFPI</sub> (SEQ ID NO: 4), or conservatively substituted variants thereof.
3. An antithrombotic composition comprising a recombinant anticoagulant protein comprising a fusion of annexin V (ANV) (SEQ ID NO: 10) and a Kunitz  
10 protease inhibitor (KPI).
4. An antithrombotic composition according to Claim 3 further comprising a pharmaceutically acceptable excipient.
5. An antithrombotic composition according to Claim 3 comprising a protein  
15 sequence selected from the group consisting of TAP-ANV (SEQ ID NO: 1), ANV-6L15 (SEQ ID NO: 2), ANV-K<sub>APP</sub> (SEQ ID NO: 3), and ANV-KK<sub>TFPI</sub> (SEQ ID NO: 4), or conservatively substituted variants thereof.
6. A method of inhibiting blood coagulation in a mammalian subject comprising administering to the subject an effective amount of a recombinant anticoagulant protein comprising a fusion of annexin V (ANV) (SEQ ID NO: 10) and a Kunitz  
20 protease inhibitor (KPI).
7. A method of producing a recombinant anticoagulant protein comprising linking annexin V (ANV) (SEQ ID NO: 10) and a Kunitz protease inhibitor (KPI).
8. A method according to claim 7 comprising generating a recombinant DNA molecule comprising a first DNA sequence encoding annexin V (ANV) (SEQ ID  
25 NO: 9) and a second DNA sequence encoding a Kunitz protease inhibitor (KPI).
9. A method according to claim 8 comprising generating a recombinant DNA molecule comprising a sequence selected from the group consisting of TAP-ANV (SEQ ID NO: 5), ANV-6L15 (SEQ ID NO: 6), ANV-K<sub>APP</sub> (SEQ ID NO: 7), and ANV-KK<sub>TFPI</sub> (SEQ ID NO: 8), or conservatively substituted variants thereof.



10. A method of treating or preventing an excess of thrombotic activity in a subject in need of such treatment or prevention, said method comprising administering to the subject an effective amount of an antithrombotic composition comprising a fusion of annexin V (ANV) (SEQ. ID NO: 10) and a Kunitz protease inhibitor (KPI).
11. A recombinant DNA molecule comprising a first DNA sequence encoding annexin V (ANV) (SEQ ID NO: 9) and second DNA sequence encoding a Kunitz protease inhibitor (KPI).
12. A recombinant DNA molecule according to claim 11 wherein said first DNA sequence comprises SEQ. ID. NO. 9 (encoding ANV), SEQ. ID. NO. 14 (encoding Cys<sup>315</sup>-to-Ala mutation of ANV), or conservatively substituted variants thereof.
13. A recombinant DNA molecule according to claim 11 comprising a DNA sequence selected from the group consisting of TAP-ANV (SEQ ID NO: 5), ANV-6L15 (SEQ ID NO: 6), ANV-K<sub>APP</sub> (SEQ ID NO: 7), and ANV-KK<sub>TFPI</sub> (SEQ ID NO: 8), or conservatively substituted variants thereof.
14. A host cell comprising a recombinant DNA molecule according to claim 11.
15. A stably transfected cell line expressing a recombinant anticoagulant protein according to claim 1.
16. A prokaryotic cell line according to claim 15.
17. A eukaryotic cell line according to claim 15.
18. A process for the preparation of a cell line expressing a recombinant anticoagulant protein comprising a fusion of annexin V (ANV) (SEQ ID NO: 10) and a Kunitz protease inhibitor (KPI), said process comprising stably transfecting a host cell with a recombinant expression vector comprising a cDNA sequence encoding ANV or conservatively substituted variants thereof, and a cDNA sequence encoding a KPI.
19. A recombinant expression vector comprising a first nucleotide sequence encoding annexin V (ANV) (SEQ ID NO: 9), Cys<sup>315</sup>-to-Ala mutation of ANV (SEQ ID NO: 14), or conservatively substituted variants thereof, and a second nucleotide sequence of a Kunitz protease inhibitor (KPI) together with additional sequences

capable of directing the synthesis of a recombinant anticoagulant protein comprising a fusion of ANV and a KPI, in a culture of stably transfected cells.

20. A recombinant expression vector according to claim 19 in a culture of stably transfected prokaryotic cells.
- 5      21. A recombinant expression vector according to claim 19 in a culture of stably transfected eukaryotic cells..
22. A recombinant expression vector according to claim 19 wherein said first nucleotide sequence comprises SEQ ID NO: 9 (encoding ANV), SEQ. ID. NO. 14 (encoding Cys<sup>315</sup>-to-Ala mutation of ANV), or conservatively substituted variants thereof.
- 10      23. A recombinant expression vector according to claim 19 comprising a nucleotide sequence selected from the group of TAP-ANV (SEQ ID NO: 5), ANV-6L15 (SEQ ID NO: 6), ANV-K<sub>APP</sub> (SEQ ID NO: 7), and ANV-KK<sub>TFPI</sub> (SEQ ID NO: 8), or conservatively substituted variants thereof.
- 15

Fig. 1




Fig. 2




Fig. 3




Fig. 4





Fig. 5



60020830-0003.ST25  
SEQUENCE LISTING

<110> wun, Tze-Chuin  
wun, Tze-Chuin

<120> Novel Recombinant Anticoagulant Proteins

<130> 60020830-0003

<160> 41

<170> PatentIn version 3.1

<210> 1

<211> 382

<212> PRT

<213> Artificial

<220>

<223> Fusion protein: human-derived ANV with TAP

<400> 1

Ala Tyr Asn Arg Leu Cys Ile Lys Pro Arg Asp Trp Ile Asp Glu Cys  
1 5 10 15

Asp Ser Asn Glu Gly Gly Glu Arg Ala Tyr Phe Arg Asn Gly Lys Gly  
20 25 30

Gly Cys Asp Ser Phe Trp Ile Cys Pro Glu Asp His Thr Gly Ala Asp  
35 40 45

Tyr Tyr Ser Ser Tyr Asn Asp Cys Phe Asn Ala Cys Ile Gly Ser Ala  
50 55 60

Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu Arg  
65 70 75 80

Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr Asp  
85 90 95

Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln Arg  
100 105 110

Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu Leu  
115 120 125

Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile Val  
130 135 140

Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys His  
145 150 155 160



60020830-0003.ST25

Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile Ile  
 165 170 175

Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr Glu  
 180 185 190

Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr Ser  
 195 200 205

Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg Asp  
 210 215 220

Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln Ala  
 225 230 235 240

Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys Phe  
 245 250 255

Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val Phe  
 260 265 270

Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile Asp  
 275 280 285

Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala Val Val Lys  
 290 295 300

Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr Ala  
 305 310 315 320

Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met Val  
 325 330 335

Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg Lys  
 340 345 350

Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser Gly  
 355 360 365

Asp Tyr Lys Lys Ala Leu Leu Leu Leu Ala Gly Glu Asp Asp  
 370 375 380

<210> 2  
 <211> 378  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Fusion protein: human-derived ANV with artificial 6L15 (a variant  
 Page 2

60020830-0003.ST25  
of naturally occurring bovine pancreatic trypsin inhibitor)

<400> 2

Ala Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu  
1 5 10 15

Arg Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr  
20 25 30

Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln  
35 40 45

Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu  
50 55 60

Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile  
65 70 75 80

Val Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys  
85 90 95

His Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile  
100 105 110

Ile Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr  
115 120 125

Glu Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr  
130 135 140

Ser Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg  
145 150 155 160

Asp Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln  
165 170 175

Ala Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys  
180 185 190

Phe Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val  
195 200 205

Phe Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile  
210 215 220

Asp Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Ala Val Val  
225 230 235 240

60020830-0003.ST25

Lys Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr  
 245 250 255

Ala Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met  
 260 265 270

Val Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg  
 275 280 285

Lys Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser  
 290 295 300

Gly Asp Tyr Lys Lys Ala Leu Leu Leu Leu Ala Gly Glu Asp Asp Met  
 305 310 315 320

His Pro Asp Phe Cys Leu Glu Pro Pro Tyr Asp Gly Pro Cys Arg Ala  
 325 330 335

Leu His Leu Arg Tyr Phe Tyr Asn Ala Lys Ala Gly Leu Cys Gln Thr  
 340 345 350

Phe Tyr Tyr Gly Gly Cys Leu Ala Lys Arg Asn Asn Phe Glu Ser Ala  
 355 360 365

Glu Asp Cys Met Arg Thr Cys Gly Gly Ala  
 370 375

<210> 3  
 <211> 376  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Fusion protein: human-derived ANV with synthetic human K-APP

<400> 3

Ala Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu  
 1 5 10 15

Arg Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr  
 20 25 30

Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln  
 35 40 45

Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu  
 50 55 60

60020830-0003.ST25

Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile  
 65 70 75 80

Val Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys  
 85 90 95

His Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile  
 100 105 110

Ile Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr  
 115 120 125

Glu Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr  
 130 135 140

Ser Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg  
 145 150 155 160

Asp Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln  
 165 170 175

Ala Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys  
 180 185 190

Phe Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val  
 195 200 205

Phe Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile  
 210 215 220

Asp Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala Val Val  
 225 230 235 240

Lys Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr  
 245 250 255

Ala Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met  
 260 265 270

Val Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg  
 275 280 285

Lys Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser  
 290 295 300

Gly Asp Tyr Lys Lys Ala Leu Leu Leu Leu Ala Gly Glu Asp Asp Glu  
 305 310 315 320

60020830-0003.ST25

Val Cys Ser Glu Gln Ala Glu Thr Gly Pro Cys Arg Ala Met Ile Ser  
 325 330 335

Arg Trp Tyr Phe Asp Val Thr Glu Gly Lys Cys Ala Pro Phe Phe Tyr  
 340 345 350

Gly Gly Cys Gly Gly Asn Arg Asn Asn Phe Asp Thr Glu Glu Tyr Cys  
 355 360 365

Met Ala Val Cys Gly Ser Ala Ile  
 370 375

<210> 4  
 <211> 459  
 <212> PRT  
 <213> Artificial

<220>  
 <223> Fusion protein: human-derived ANV with KK-TFPI (a human sequence)

<400> 4

Ala Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu  
 1 5 10 15

Arg Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr  
 20 25 30

Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln  
 35 40 45

Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu  
 50 55 60

Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile  
 65 70 75 80

Val Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys  
 85 90 95

His Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile  
 100 105 110

Ile Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr  
 115 120 125

Glu Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr  
 130 135 140

60020830-0003.ST25

Ser Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg  
 145 150 155 160

Asp Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln  
 165 170 175

Ala Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys  
 180 185 190

Phe Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val  
 195 200 205

Phe Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile  
 210 215 220

Asp Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala Val Val  
 225 230 235 240

Lys Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr  
 245 250 255

Ala Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met  
 260 265 270

Val Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg  
 275 280 285

Lys Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser  
 290 295 300

Gly Asp Tyr Lys Lys Ala Leu Leu Leu Ala Gly Glu Asp Asp Met  
 305 310 315 320

His Ser Phe Cys Ala Phe Lys Ala Asp Asp Gly Pro Cys Lys Ala Ile  
 325 330 335

Met Lys Arg Phe Phe Phe Asn Ile Phe Thr Arg Gln Cys Glu Glu Phe  
 340 345 350

Ile Tyr Gly Gly Cys Glu Gly Asn Gln Asn Arg Phe Glu Ser Leu Glu  
 355 360 365

Glu Cys Lys Lys Met Cys Thr Arg Asp Asn Ala Asn Arg Ile Ile Lys  
 370 375 380

Thr Thr Leu Gln Gln Glu Lys Pro Asp Phe Cys Phe Leu Glu Glu Asp  
 385 390 395 400

60020830-0003.ST25

Pro Gly Ile Cys Arg Gly Tyr Ile Thr Arg Tyr Phe Tyr Asn Gln  
 405 410 415

Thr Lys Gln Cys Glu Arg Phe Lys Tyr Gly Gly Cys Leu Gly Asn Met  
 420 425 430

Asn Asn Phe Glu Thr Leu Glu Glu Cys Lys Asn Ile Cys Glu Asp Gly  
 435 440 445

Pro Asn Gly Phe Gln Val Asp Asn Tyr Gly Thr  
 450 455

<210> 5  
 <211> 1380  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Fusion gene of human-derived ANV with TAP

<400> 5  
 gcacagggtc tcagaggcac ttgtactgac ttccctggat ttgatgagcg ggctgatgca 60  
 gaaactcttc ggaaggctat gaaaggcttg ggcacagatg aggagagcat cctgactctg 120  
 ttgacatccc gaagtaatgc tcagcgccag gaaatctctg cagcttttaa gactctgttt 180  
 ggcagggatc ttctggatga cctgaaatca gaactaactg gaaaatttga aaaattaatt 240  
 gtggctctga tgaacccttc tcggctttat gatgcttatg aactgaaaca tgccttgaag 300  
 ggagctggaa caaatgaaa agtactgaca gaaattattg ctccaaggac acctgaagaa 360  
 ctgagagcca tcaacaagt ttatgaagaa gaatatggct caagcctgga agatgacgtg 420  
 gtgggggaca cttcagggtg ctaccagcgg atgttggtgg ttctccttca ggctaacaga 480  
 gacctgatg ctggaattga tgaagctcaa gttgaacaag atgctcaggc tttatttcag 540  
 gctggagaac ttaaatgggg gacagatgaa gaaaagttaa tcaccatctt tggaaacacga 600  
 agtgtgtctc atttgagaaa ggtgtttgac aagtacatga ctatatcagg atttcaaatt 660  
 gaggaacca ttgaccgca gacttctggc aatttagagc aactactcct tgctgttgtg 720  
 aaatctattc gaagtatac tgccatcctt gcagagaccc tctattatgc tatgaaggga 780  
 gctgggacag atgatcatac cctcatcaga gtcatgggtt ccaggagatga gattgatctg 840  
 tttaacatca ggaaggagtt taggaagaat ttggcacct ctctttattc catgattaaag 900  
 ggagatcatc ctggggacta taagaaagct cttctgctgc tcgtggaga agatgacatg 960  
 cattcatttt gtgcattcaa ggcggatgat ggcccatgta aagcaatcat gaaaagattt 1020  
 ttcttcaata ttttactctg acagtgcgaa gaatttatat atgggggatg tgaaggaaat 1080  
 cagaatcgat ttgaaagtct ggaagagtgc aaaaaaatgt gtacaagaga taatgcaaac 1140

60020830-0003.ST25

aggattataa agacaacatt gcaacaagaa aagccagatt tctgcttttt ggaagaagat	1200
cctggaatat gtcgaggtta tattaccagg tatttttata acaatcagac aaacacagtgt	1260
gaacgtttca agtatggtgg atcgctgggc aatatgaaca attttgagac actggaagaa	1320
tgcagaaca tttgtgaaga tgggtccgaat ggtttccagg tggataatta tggaaacctaa	1380

<210> 6  
 <211> 1137  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Fusion gene of human-derived ANV with artificial 6L15, which is a variant of naturally occurring bovine pancreatic trypsin inhibitor or

<400> 6	
gcacaggttc tcagaggcac tgtgactgac ttccctggat ttgatgagcg ggctgatgca	60
gaaactcttc ggaaggctat gaaaggcttg ggcacagatg aggagagcat cctgactctg	120
ttgacatccc gaagtaatgc tcagcgccag gaaatctctg cagcttttaa gactctgttt	180
ggcagggatc ttctggatga cctgaaatca gaactaactg gaaaatttga aaaattaatt	240
gtggctctga tgaaccttc tcggctttat gatgcttatg aactgaaaca tgccttgaag	300
ggagctggaa caaatgaaa agtactgaca gaaattattg cttcaaggac acctgaagaa	360
ctgagagcca tcaacaagt ttatgaagaa gaatatggct caagcctgga agatgacgtg	420
gtgggggaca cttcagggtta ctaccagcgg atgttggtgg ttctccttca ggctaacaga	480
gaccttgatg ctggaattga tgaagctcaa gttgaacaag atgctcaggc tttatttcag	540
gctggagaac ttaaatgggg gacagatgaa gaaaagttaa tcaccatctt tggaaacaga	600
agtgtgtctc atttgagaaa ggtgtttgac aagtacatga ctatatcagg atttcaaat	660
gaggaaacca ttgaccgcga gacttctggc aatttagagc aactactcct tgctgttgtg	720
aaatctattc gaagtatacc tgcctacctt gcagagacc tctattatgc tatgaaggga	780
gctgggacag atgatacat cctcatcaga gtcattggtt ccaggagtga gattgatctg	840
tttaacatca ggaaggagtt taggaagaat ttgcccact ctctttatc catgattaag	900
ggagatacat ctggggacta taagaaagct cttctgctgc tcgctggaga agatgacatg	960
catccggact tctgcttgga accgccgtac gacgggtccgt gccgtgctct gcacctgcgt	1020
tacttctaca atgcaaaagc aggcctgtgt cagaccttct actacggcgg ttgctggct	1080
aagcgtaaca acttcgaatc cgcggaagac tgcattgcgt cttgcggtgg tgcttaa	1137

<210> 7  
 <211> 1131  
 <212> DNA



60020830-0003.ST25

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Fusion gene of human-derived ANV with synthetic human K-APP gene

```

<400> 7
gcacagggtc tcagaggcac tgtgactgac ttccctggat ttgatgagcg ggctgatgca 60
gaaactcttc ggaaggctat gaaaggcttg ggcacagatg aggagagcat cctgactctg 120
ttgacatccc gaagtaatgc tcagcgccag gaaatctctg cagcttttaa gactctgttt 180
ggcagggatc ttctggatga cctgaaatca gaactaactg gaaaatttga aaaattaatt 240
gtggctctga tgaacccttc tcggctttat gatgcttatg aactgaaaca tgccctgaag 300
ggagctggaa caaatgaaaa agtactgaca gaaattattg cttcaaggac acctgaagaa 360
ctgagagcca tcaacaagt ttatgaagza gaatatggct caagcctgga agatgacgtg 420
gtgggggaca cttcagggtg ctaccagcgg atgttgggtg ttctccttca ggctaacaga 480
gacctgatg ctggaattga tgaagctcaa gttgaacaag atgtcaggcg tttatttcag 540
gctggagaac ttaaatgggg gacagatgaa gaaaagtta tcaccatctt tggaacacga 600
agtgtgtctc atttgagaaa ggtgtttgac aagtacatga ctatatcag atttcaaatt 660
gaggaaccca ttgaccgcga gacttctggc aatttagagc aactactcct tgctgttgg 720
aaatctattc gaagtatacc tgcctacctt gcagagaccc tctattatgc tatgaaggga 780
gctgggacag atgatcatac cctcatcaga gtcatggttt ccaggagtga gattgatctg 840
tttaacatca ggaaggagtt taggaagaat ttgcccact ctctttatc catgattaag 900
ggagatacat ctggggacta taagaaagct cttctgctgc tcgctggaga agatgacgag 960
gtttgttctg agcaagctga gactgggtcca tgtagagcta tgatttctag atggactctc 1020
gacgttactg agggtaagtg tgctccattc ttctacggtg gttgtgggtg taacagaaac 1080
aacttcgaca ctgaggagta ctgtatggct gttgtgggtt ctgctattta a 1131

```

&lt;210&gt; 8

&lt;211&gt; 1380

&lt;212&gt; DNA

&lt;213&gt; Artificial

&lt;220&gt;

&lt;223&gt; Fusion gene of human-derived ANV with KK-TFPI, which is a human s equence

```

<400> 8
gcacagggtc tcagaggcac tgtgactgac ttccctggat ttgatgagcg ggctgatgca 60
gaaactcttc ggaaggctat gaaaggcttg ggcacagatg aggagagcat cctgactctg 120
ttgacatccc gaagtaatgc tcagcgccag gaaatctctg cagcttttaa gactctgttt 180
ggcagggatc ttctggatga cctgaaatca gaactaactg gaaaatttga aaaattaatt 240

```

60020830-0003.ST25

gtggctctga	tgaaccctc	tcggctttat	gatgcttatg	aactgaaaca	tgccctgaag	300
ggagctggaa	caaatgaaaa	agtactgaca	gaaattattg	cttcaaggac	acctgaagaa	360
ctgagagcca	tcaacaagt	ttatgaagaa	gaatatggct	caagcctgga	agatgacgtg	420
gtgggggaca	cttcagggtg	ctaccagcgg	atgttggtgg	ttctccttca	ggctaacaga	480
gacctgatg	ctggaattga	tgaagctcaa	gttgaacaag	atgctcaggc	tttatttcag	540
gctggagaac	ttaaatgggg	gacagatgaa	gaaaagttta	tcaccatctt	tggaacacga	600
agtgtgtctc	atttgagaaa	ggtgtttgac	aagtacatga	ctatatcagg	atttcaaat	660
gaggaaacca	ttgaccgca	gacttctgyc	aatttagagc	aactactcct	tgctgtgttg	720
aaatctattc	gaagtatacc	tgctacactt	gcagagaccc	tctattatgc	tatgaaggga	780
gctgggacag	atgatcatat	cctcatcaga	gtcatggttt	ccaggagtga	gattgatctg	840
tttaacatca	ggaaggagtt	taggaagaat	tttgccacct	ctctttattc	catgattaag	900
ggagatcat	ctggggacta	taagaaagct	cttctgctgc	tcgctggaga	agatgacatg	960
cattcatttt	gtgcattcaa	ggcggatgat	ggcccatgta	aagcaatcat	gaaaagattt	1020
ttcttcaata	ttttcactcg	acagtgcgaa	gaatttatat	atgggggatg	tgaaggaaat	1080
cagaatcgat	ttgaaagtct	ggaagagtgc	aaaaaatgt	gtacaagaga	taatgcacaa	1140
aggattataa	agacaacatt	gcaacaagaa	aagccagatt	ttgctttttt	ggaagaagat	1200
cctggaatat	gtcagaggta	tattaccagg	tatttttata	acaatcagac	aaaacagtgt	1260
gaacgtttca	agtatggtgg	atcgtgtggc	aatatgaaca	attttgagac	actggaagaa	1320
tgcaagaaca	tttgtgaaga	tggtccgaat	ggtttccagg	tggaataatta	tggaacctaa	1380

<210> 9  
 <211> 960  
 <212> DNA  
 <213> Homo sapiens

<400> 9	
gcacaggctc	tcagaggcac
gtgactgac	ttccctggat
ttgatgagcg	ggctgatgca
gaaactcttc	ggaaggctat
gaaaggcttg	ggcacagatg
aggagagcat	cctgactctg
ttgacatccc	gaagtaatgc
tcagcgccag	gaaatctctg
cagcttttaa	gactctgttt
ggcagggatc	ttctggatga
cctgaaatca	gaactaactg
gaaaatttga	aaaattaatt
gtggctctga	tgaaccctc
tcggctttat	gatgcttatg
aactgaaaca	tgccctgaag
ggagctggaa	caaatgaaaa
agtactgaca	gaaattattg
cttcaaggac	acctgaagaa
ctgagagcca	tcaacaagt
ttatgaagaa	gaatatggct
caagcctgga	agatgacgtg
gtgggggaca	cttcagggtg
ctaccagcgg	atgttggtgg
ttctccttca	ggctaacaga
gacctgatg	ctggaattga
tgaagctcaa	gttgaacaag
atgctcaggc	tttatttcag

60020830-0003.ST25

```

gctggagaac ttaaatgggg gacagatgaa gaaaagttaa tcaccatctt tggaacacga    600
agtgtgtctc atttgagaaa ggtgtttgac aagtacatga ctatatacagg atttcaaatt    660
gaggaacca ttgaccgcga gacttctggc aatttagagc aactactcct tgctgtgtg    720
aaatctattc gaagtatacc tgccctacct gcagagaccc tctattatgc tatgaaggga    780
gctgggacag atgatcatac cctcatcaga gtcattggtt ccaggagtga gattgatctg    840
tttaacatca ggaaggagtt taggaagaat ttgccacct ctctttattc catgattaag    900
ggagatacat ctggggacta taagaaagct cttctgctgc tctgtggaga agatgactaa    960

```

```

<210> 10
<211> 319
<212> PRT
<213> Homo sapiens

```

```

<400> 10

```

```

Ala Gln Val Leu Arg Gly Thr Val Thr Asp Phe Pro Gly Phe Asp Glu
1      5      10

```

```

Arg Ala Asp Ala Glu Thr Leu Arg Lys Ala Met Lys Gly Leu Gly Thr
20     25     30

```

```

Asp Glu Glu Ser Ile Leu Thr Leu Leu Thr Ser Arg Ser Asn Ala Gln
35     40     45

```

```

Arg Gln Glu Ile Ser Ala Ala Phe Lys Thr Leu Phe Gly Arg Asp Leu
50     55     60

```

```

Leu Asp Asp Leu Lys Ser Glu Leu Thr Gly Lys Phe Glu Lys Leu Ile
65     70     75     80

```

```

Val Ala Leu Met Lys Pro Ser Arg Leu Tyr Asp Ala Tyr Glu Leu Lys
85     90     95

```

```

His Ala Leu Lys Gly Ala Gly Thr Asn Glu Lys Val Leu Thr Glu Ile
100    105    110

```

```

Ile Ala Ser Arg Thr Pro Glu Glu Leu Arg Ala Ile Lys Gln Val Tyr
115    120    125

```

```

Glu Glu Glu Tyr Gly Ser Ser Leu Glu Asp Asp Val Val Gly Asp Thr
130    135    140

```

```

Ser Gly Tyr Tyr Gln Arg Met Leu Val Val Leu Leu Gln Ala Asn Arg
145    150    155    160

```

60020830-0003.ST25

Asp Pro Asp Ala Gly Ile Asp Glu Ala Gln Val Glu Gln Asp Ala Gln  
 165 170 175

Ala Leu Phe Gln Ala Gly Glu Leu Lys Trp Gly Thr Asp Glu Glu Lys  
 180 185 190

Phe Ile Thr Ile Phe Gly Thr Arg Ser Val Ser His Leu Arg Lys Val  
 195 200 205

Phe Asp Lys Tyr Met Thr Ile Ser Gly Phe Gln Ile Glu Glu Thr Ile  
 210 215 220

Asp Arg Glu Thr Ser Gly Asn Leu Glu Gln Leu Leu Leu Ala Val Val  
 225 230 235 240

Lys Ser Ile Arg Ser Ile Pro Ala Tyr Leu Ala Glu Thr Leu Tyr Tyr  
 245 250 255

Ala Met Lys Gly Ala Gly Thr Asp Asp His Thr Leu Ile Arg Val Met  
 260 265 270

Val Ser Arg Ser Glu Ile Asp Leu Phe Asn Ile Arg Lys Glu Phe Arg  
 275 280 285

Lys Asn Phe Ala Thr Ser Leu Tyr Ser Met Ile Lys Gly Asp Thr Ser  
 290 295 300

Gly Asp Tyr Lys Lys Ala Leu Leu Leu Leu Cys Gly Glu Asp Asp  
 305 310 315

<210> 11  
 <211> 33  
 <212> DNA  
 <213> Artificial

<220>  
 <223> ANV reverse primer

<400> 11  
 atcaagctta tgcgtgcat cttctccaca gag

33

<210> 12  
 <211> 31  
 <212> DNA  
 <213> Artificial

<220>  
 <223> ANV forward primer

<400> 12  
 gatcggatcc agtcgtgtcc tgcctcacc t

31

60020830-0003.ST25

<210> 13  
 <211> 32  
 <212> DNA  
 <213> Artificial

<220>  
 <223> synthetic oligonucleotide used to generate ANV cDNA mutation of Cys-to-Ala at position 315

<400> 13  
 cgtgacatgc atgtcatctt ctccagcgag ca

32

<210> 14  
 <211> 960  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Sequence encoding human ANV with Cys-to-Ala mutation at position 315

<400> 14  
 gcacaggttc tcagaggcac tgtgactgac ttccctggat ttgatgagcg ggctgatgca 60  
 gaaactcttc ggaaggctat gaaaggcttg ggcacagatg aggagagcat cctgactctg 120  
 ttgacatccc gaagtaatgc tcagcgccag gaaatctctg cagcttttaa gactctgttt 180  
 ggcagggatc ttctggatga cctgaaatca gaactaactg gaaaatttga aaaatttaatt 240  
 gtggctctga tgaaccctc tcggctttat gatgcttatg aactgaaaca tgccttgaag 300  
 ggagctggaa caaatgaaaa agtactgaca gaaattattg ctccaaggac acctgaagaa 360  
 ctgagagcca tcaaacaaagt ttatgaagaa gaatatggct caagcctgga agatgacgtg 420  
 gtgggggaca cttcagggtg ctaccagcgg atgttgggtg ttctccttca ggctaacaga 480  
 gacctgatg ctggaattga tgaagctcaa gttgaacaag atgctcaggc tttatttcag 540  
 gctggagaac ttaaatgggg gacagatgaa gaaaagtta tcaccatctt tggaaacaga 600  
 agtgtgtctc atttgagaaa ggtgtttgac aagtacatga ctatatcagg atttcaaatt 660  
 gaggaaacca ttgaccgcga gacttctggc aatttagagc aactactcct tgcgttgttg 720  
 aaatctattc gaagtatacc tgcctacctt gcagagaccc tctattatgc tatgaaggga 780  
 gctgggacag atgatacat cctcatcaga gtcattggtt ccaggagtga gattgatctg 840  
 tttaacatca ggaaggagtt taggaagaat ttggccacct ctctttatc catgattaa 900  
 ggagatacat ctggggacta taagaagct cttctgctgc tcgctggaga agatgactaa 960

<210> 15  
 <211> 64  
 <212> DNA  
 <213> Artificial

<220>

60020830-0003.ST25

<223> Synthetic oligonucleotide, first of three forward primers used to generate recombinant 6L15 gene

<400> 15  
 tccggacttc tgcctggaac cgccgtacga cggctccgtgc cgtgctctgc acctgcgtta . 60  
 cttc 64

<210> 16  
 <211> 60  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide, second of three forward primers used to generate recombinant 6L15 gene

<400> 16  
 tacaatgcaa aggcaggcct gtgtcagacc ttctactacg gcggttgctt ggctaagcgt 60

<210> 17  
 <211> 50  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide, third of three forward primers used to generate recombinant 6L15 gene

<400> 17  
 aacaacttcg aatccgcgga acactgcatg cgtacttgcg gtggtgctta 50

<210> 18  
 <211> 63  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide, first of three reverse primers used to generate recombinant 6L15 gene

<400> 18  
 acgcaggtgc agagcacggc acggaccgtc gtacggcggt tccaggcaga agtccggatg 60  
 cat 63

<210> 19  
 <211> 60  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide, second of three reverse primers used to generate recombinant 6L15 gene

<400> 19  
 agccaggcaa ccgccgtagt agaaggtctg acacaggcct gcctttgcat tgtagaagta 60

60020830-0003.ST25

<210> 20  
 <211> 60  
 <212> DNA  
 <213> Artificial

<220>  
 <223> Synthetic oligonucleotide, third of three reverse primers used to generate recombinant 6L15 gene

<400> 20  
 agcttaagca ccaccgcaag tacgcatgca gtcttccgcg gattcgaagt tgttacgctt 60

<210> 21  
 <211> 177  
 <212> DNA  
 <213> Artificial

<220>  
 <223> synthetic 6L15 gene

<400> 21  
 gtcccgact tctgcctgga accgccgtac gacggtccgt gccgtgctct gcacctgcgt 60  
 tactttaca atgcaaaaggc aggcctgtgt cagaccttct actacggcgg ttgcctggct 120  
 aagcgaaca acttcgaatc cgcggaagac tgcattgcga cttcggtggt tgcttaa 177

<210> 22  
 <211> 186  
 <212> DNA  
 <213> Artificial

<220>  
 <223> synthetic, derived from Ornithodoros moubata gene

<400> 22  
 gcttacaacc gtctgtgcat caaaccgcgt gactggatcg acgaatgcga ctccaacgaa 60  
 ggtggtgaac gtgcttactt ccgtaacggt aaaggtggtt gcgactcctt ctggatctgc 120  
 ccggaagacc acaccgggtc tgactactac tctctctacc gtgactgctt caacgcttgc 180  
 atctaa 186

<210> 23  
 <211> 122  
 <212> DNA  
 <213> Artificial

<220>  
 <223> forward synthetic oligonucleotide for generating synthetic K-APP gene with flanking sequences

<400> 23  
 ggcctacacc cacagatagc gagttgccac cactgaaact tgaggtgtgt agagaggttt 60  
 gttctgagca agctgagact ggtccatgta gagctatgat ttctagatgg tacttcgacg 120  
 tt 122

60020830-0003.ST25

<210> 24  
 <211> 117  
 <212> DNA  
 <213> Artificial

<220>  
 <223> forward synthetic oligonucleotide for generating synthetic K-APP gene with flanking sequences

<400> 24  
 actgagggtta agtgtgctcc attctttctac ggtgggttggt gtggtaacag aaacaacttc 60  
 gacactgagg agtactgtat ggctgtttgt ggttctgcta tttaaagtca ttgatga 117

<210> 25  
 <211> 124  
 <212> DNA  
 <213> Artificial

<220>  
 <223> reverse synthetic oligonucleotide for generating synthetic K-APP gene with flanking sequences

<400> 25  
 ctcagtaacg tcgaagtacc atctagaaat catagctcta catggaccag tctcagcttg 60  
 ctcagaacaa acctctctaa caacctcaag ttctagtggg ggcaactccg tatctgtggg 120  
 gtag 124

<210> 26  
 <211> 115  
 <212> DNA  
 <213> Artificial

<220>  
 <223> reverse synthetic oligonucleotide for generating synthetic K-APP gene with flanking sequences

<400> 26  
 agcttcacat atgcatttaa atagcagaac cacaacacgc catacagtac tcctcagtg 60  
 cgaagtgttt tctgttacca ccacaaccac cgtagaagaa tggagcacac ttacc 115

<210> 27  
 <211> 174  
 <212> DNA  
 <213> Artificial

<220>  
 <223> synthetic K-APP gene, derived from human sequence

<400> 27  
 gaggtttggt ctgagcaagc tgagactggt ccatgtagag ctatgatttc tagatggtac 60  
 ttccagctta ctgagggtta gtgtgctcca ttcttctacg gtgggttggtg tggtaacaga 120  
 aacaacttcg aactgagga gtactgtatg gctgtttgtg gttctgctat ttaa 174



60020830-0003.ST25

<210> 28  
 <211> 30  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 28  
 ggaattccat atggcacagg ttctcagagg

30

<210> 29  
 <211> 24  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 29  
 ccaatgcatg tcattttctc cagc

24

<210> 30  
 <211> 24  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 30  
 ccaatgcac cggaattctg cctg

24

<210> 31  
 <211> 24  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 31  
 ccaatgcatt cattttgtgc attc

24

<210> 32  
 <211> 27  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer

<400> 32  
 acgcgtcgac ttaagcacca ccgcaag

27

<210> 33  
 <211> 29

60020830-0003.ST25

<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 33  
acgcgtcgac ttaggttcca taattatcc 29

<210> 34  
<211> 30  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 34  
ggaattccat atggcttaca accgtctgtg 30

<210> 35  
<211> 27  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 35  
cgggatccga tgcaagcgtt-gaagcag 27

<210> 36  
<211> 26  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 36  
cgggatccgc acaggttctc agaggc 26

<210> 37  
<211> 29  
<212> DNA  
<213> Artificial

<220>  
<223> primer

<400> 37  
acgcgtcgac ttagtcatct tctccagcg 29

<210> 38  
<211> 31  
<212> DNA  
<213> Artificial

60020830-0003.ST25

<220>  
 <223> primer designed for generating PCR fragment of interest for cloning into vector pPIC9

<400> 38  
 ccgctcgaga aaagagcaca gggtctcaga g 31

<210> 39  
 <211> 33  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer designed for generating PCR fragment of interest for cloning into yeast expression vector pPIC9

<400> 39  
 ataagaatgc ggccgcttaa atagcagaac cac 33

<210> 40  
 <211> 24  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer designed for generating PCR fragment of interest for cloning into yeast expression vector pPIC9

<400> 40  
 cgcgatatca tcttctccag cgag 24

<210> 41  
 <211> 20  
 <212> DNA  
 <213> Artificial

<220>  
 <223> primer designed for generating PCR fragments of interest for cloning into yeast expression vector pPIC9

<400> 41  
 gaggtttgtt ctgagcaagc\_ 20